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2 Abbreviations 
ADME Absorption, Distribution, Metabolism, Excretion  
ATC Anatomical Therapeutic Chemical classification system 
AUC Area Under the Curve 
BEDROC Boltzmann-Enhanced Discrimination of ROC 
BN-BMLA Bayesian Network based Bayesian Multilevel Analysis 
BPMF Bayesian Probabilistic Matrix Factorization 
CNS Central Nervous System 
COM Composition of Matter (patent) 
CROC Concentrated ROC 
CSEA Compound Set Enrichment Analysis 
DAG Directed Acyclic Graph 
EF Enrichment Factor 
FDA Food and Drug Administration 
FN False Negative 
FP False Positive 
GO Gene Ontology 
GSEA Gene Set Enrichment Analysis 
HCI High Content Imaging 
HDACi Histone deacetylase inhibitor 
HLGT High Level Group Term (MedDRA) 
HLT High Level Term (MedDRA) 
HPO Human Phenotype Ontology 
HTS High Throughput Screening 
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IND Investigational New Drug 
INN International Nonproprietary Name 
IR Infrared (spectroscopy) 
ISS IntraSet Similarity 
KFR Kernel Fusion Repositioning 
LLT Lowest Level Term (MedDRA) 
MAF Minor Allele Frequency 
MAO-B Monoamine Oxidase B 
MCMC Markov-Chain Monte Carlo 
MeSH Medical Subject Headings 
MKL Multiple Kernel Learning 
MOU Method of Use (Patent) 
NME New Molecular Entity 
NMR Nuclear Magnetic Resonance 
OLS Ordinary Least Squares 
PCA Principal Component Analysis 
PCR Principal Component Regression 
PGM Probabilistic Graphical Model 
PLS Partial Least Squares regression 
PPARγ Peroxisome proliferator-activated receptor gamma 
PPI Protein-Protein Interaction (network) 
PT Preferred Term (MedDRA) 
PU Positive and Unlabelled (learning) 
QSAR Quantitative Structure-Activity Relationship 
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RBF Radial Basis Function (kernel) 
ROC Receiver Operating Characteristic curve 
ROS Reactive Oxygen Species 
SAR Structure-Activity Relationship 
SEA Similarity Ensemble Approach 
SMARTS Smiles Arbitrary Target Specification 
SNP Single Nucleotide Polymorphism 
SNRI Serotonin-Norepinephrine Reuptake Inhibitor 
SOC System Organ Class (MedDRA) 
SSRI Selective Serotonin Reuptake Inhibitor 
SUI Stress Urinary Incontinence 
TN True Negative 
TP True Positive 
UAS Universal Average Similarity 
UMLS Unified Medical Language System 
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3 Introduction 
As the productivity of the pharmaceutical research and development is lagging behind the 
sharply increasing costs, the pharmaceutical industry is continuously searching for new 
approaches in drug discovery. These problems are aggravated also by the price pressure 
caused by expiring patents, and the ever complicated regulatory procedures. In my 
doctoral research I developed and applied methods related to two topics, which 
revolutionized the pharmaceutical industry to ameliorate the effect of the dropping 
effectiveness of the research and development pipeline: drug repositioning and 
personalized medicine (Figure 1). 
 
Figure 1 – The investigated topics and their common characteristics. 
 Drug repositioning or repurposing is a cost-effective and risk-reducing straightforward 
strategy, which aims at reusing already approved drugs in new therapeutic indications. 
From the machine learning perspective the main distinctive feature of drug repositioning 
Figure 2 - Topics related to drug repositioning and their relations. 
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compared to de novo drug discovery is the availability of a wide range of information 
sources. While conducting the research my primary goal was to develop computational 
methods to harness these information sources in drug repositioning (see Figure 2). As a 
first step I created a benchmark dataset containing six different information sources (three 
chemical structure descriptors, two side effect based descriptors and a target profile), and 
a drug-indication gold standard set. The goal of my first computational experiment was 
to compare a novel data fusion methodology, called Kernel Fusion Repositioning (KFR), 
with a baseline method. My contribution primarily concerned   the design and 
implementation of the KFR framework as well as the application of the KFR framework 
on the problem of repositioning for Parkinson’s disease. As one of the authors of a novel 
multi-target prediction method I also applied this method to the repositioning benchmark, 
and analysed the effect of multi-target learning on accuracy. 
My second topic was related to personalized medication, which facilitates the optimal 
therapy for the patient and is also favourable for the researcher interested in drug 
development. Predicting the patient-by-patient variability of the pharmacokinetics can 
help the investigator adjust the doses in a personalized way in order to maximize efficacy 
and minimize side effects and toxicity. I participated in researching the interpersonal 
variability of methotrexate pharmacokinetics at high dose levels, developed new clinical 
descriptors bridging patient and treatment levels, and investigated their usage by applying 
a novel Bayesian multivariate statistical technique to identify predictive genetic variants. 
Moreover, I compared the results against already existing ones based on frequentist 
statistics. 
3.1 Pharmaceutical Industry Background 
The past two decades in the pharmaceutical industry have been characterized by 
decreasing research and development productivity, high attrition rate and high volatility 
of output. Nowadays a dramatic shift has taken place in the field, including more pre-
competition time collaborations, public-private partnerships, and an extremely high 
number of mergers and acquisitions [1]. The cost of developing a new drug is steadily 
increasing, while the yearly number of accepted New Molecular Entities (NMEs) is 
constant or even decreasing regarding only the small molecular drugs. These trends 
clearly show that the productivity of the pharmaceutical research and development sector 
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is deteriorating and the complexity of developing a new drug and the time needed for it 
is growing significantly [2]. One of the several possible causes of this increased 
complexity is the stricter regulation environment well illustrated by the increasing 
number of guidelines [3]. 
The concentration of research and development efforts in therapeutic areas with larger 
patient population and higher risk, like chronic and potentially lethal diseases can be 
observed. A significant exception is the case of rare or orphan diseases, where 
governmental regulation, like the US Orphan Drug Act and the Regulation (EC) 141/2000 
in the EU influence the market [2]. 
A somewhat radical suggestion to change the patent and the regulatory system has been 
also discussed in the literature [3]. It is generally accepted that the pharmaceutical 
industry heavily uses the patent system and employs defensive strategies which can be 
counterproductive and can further decrease productivity through feedback loops. In the 
recent years the fear of sharing information seems to ease, but it is still quite prominent. 
Another way to move the system to a more cooperative mode of operation is to encourage 
the cooperation between the academia and the industry in a way that protects the academic 
focus on the long-term goals and high risk innovation. 
 The history of modern pharmaceutical industry was started by the large scale 
manufacturing of penicillin. At that time regulation was less strict, only safety studies 
were required for approval. Essential changes have taken place after the Contergan case, 
which have led to the introduction of the drug law, the ”Arzneimittelgesetz” in Germany, 
and with a bit logical jump to the Hatch-Waxman act in the USA [4, 5]. 
In the United States a notable step toward the current regulatory system was the enactment 
of the Drug Price Competition and Patent Term Restoration Act, often referred to as the 
Hatch-Waxman Act in 1984. It is useful to shortly examine this law, because it has 
indirect effects to the pharmaceutical development in the entire world. The main goal of 
the act is to facilitate generic development and price competition. It is achieved firstly by 
declaring the sufficiency of bioequivalence studies for generic product approval. A 
generic company can now enter the market by showing with bioavailability studies that 
their product is equivalent to the original medicine. The originator always has a 5 year 
data exclusivity period from approval. During this time the original clinical trials cannot 
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be used in the registration process of the generic competitor product. As a kind of 
compensation to stimulate research, patent term restoration has been introduced, which 
means that half of the time spent between the patent submission and the beginning of the 
marketing period, but maximum 5 years, can be added to the market exclusivity period 
of the originator. The whole exclusivity period cannot be longer than 14 years.  
In the pharmaceutical industry remarkable volatility of the approval rate appeared in the 
mid-90s. However a dramatic market entry-exit volatility already existed in the 80s, 
increased explosively in the 90s and the first decade of the 2000s due to mergers and 
acquisitions. These trends led to an increasing number of managed NME per organisation. 
This concentration of patented products led to the birth of a new type of market player, 
the 'Big Pharma'. Many of these companies do not carry out direct research and 
development activity or only in limited number, but obtaining NMEs by acquisitions of 
small companies instead [1]. 
Historically the time needed for developing a drug from the first screen was 10-15 years, 
but now this pipeline length is increasing. A target discovery phase, where the main 
question is the relevance of a target in a particular disease, usually precedes the de novo 
development, but this is out of the scope of the present work. The identification of the 
compounds starts with in-vitro or in-silico screening, usually High Throughput Screening 
(HTS) or virtual screening, where the goal is to search for hits, molecules with high 
probability of target binding. The preclinical development phase in a broader sense 
includes the classical chemical development steps such as hit-to-lead transition, lead 
optimization (changing substitution) and synthesis scale up. Strictly speaking the 
preclinical studies are experiments carried out to prove that the compound is safe to start 
human studies. These experiments include metabolic stability assays, toxicology studies 
and limited efficacy studies on model organisms. Before an experimental compound can 
be tested on human subjects, it need to be registered at the authority as an investigational 
new drug (IND). The Human Clinical Trials are divided into phases. During the Phase I 
studies, the main goal is to characterize the safety profile of the compound: determine the 
maximal safe dose and the absorption, distribution, metabolism, excretion profile (ADME) 
using increasing doses. These trials are usually carried out with the involvement of 100 
or less healthy volunteers. In special indications like cancer a more frequent adverse 
reaction is acceptable in the hope of the expected favourable risk-benefit ratio. In this case 
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the safety study, usually called Phase I/II study, involves patients and the determination 
of a small sample based estimate of the efficacy is also possible. In Phase II the goal is 
the determination of human therapeutic efficacy with participation of limited number, 
typically hundreds, of patients. This phase is sometimes divided into sub-phases, like II/A 
and II/B. The classical setup is a double-blind placebo controlled setting, but it is not 
always applicable. If an already established therapy exists for the disease, for ethical 
reasons the control is frequently that existing therapy, and the new compound is given on 
its own or as an add-on to the classical therapy. The Phase III trial is an extension of the 
Phase II to 5-8000 patients as a multicentre trial. The successful closure of the Phase III 
is an essential prerequisite for a regulatory approval. If an already approved drug is tested 
and found effective in a new indication, a regulatory submission is made for label 
expansion. This type of submission has considerable interest concerning this work. The 
process is not finished at the point of approval. The final phase of the compound's 
lifecycle is the postmarketing phase, or Phase IV, which is about the continuous 
monitoring of safety also known as pharmacovigilance [6]. The manufacturers together 
with the medical doctors and the patients continuously monitor adverse events. The 
continuous data acquisition and interim analysis is pervasive during the whole pipeline 
both for ethical and financial reasons [7]. In the European Union the 'Community code 
relating to medicinal products for human use' (Directive 2001/83/EC) outlines the main 
regulatory background. 
Regarding the detailed structure of the unsuccessful cases in the 2011-2012 interval, the 
main cause of failure in Phase II and III Clinical Trials was the lack of efficacy (56%), 
followed by safety issues (28%) [8].  The most expensive failure is which happens during 
Phase III; therefore early termination of the probably unsuccessful projects is an interest 
of the company. This fail-fast approach can be an explanation for the increase of attrition 
rate in Phase II and the decrease of failure rate in Phase III. It is worth pointing out that 
the rate of safety failures increased significantly during Phase III, which can serve as a 
motivation for this work, because suggesting approved and safe drugs for new indications 
can decrease the number of safety failures [8]. An analysis from 2014 suggests that the 
research and development output of the industry is still not satisfactory [9]. 
Drug repositioning or repurposing, i.e. searching for an innovative therapeutic application 
for an old drug, is a cost-effective and risk-reducing strategy in pharmaceutical research 
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and development.  For an existing compound already approved as a drug in some 
indications toxicity and pharmacokinetics parameters like ADME profile are available at 
least in some dosage and for some routes of administration [10]. The already developed 
manufacturing process or synthesis scale-up can also lower the costs. 
The classical case of drug repositioning is when a late failed candidate repositioned to a 
new indication. The serendipitous observation which led to the repositioning of 
thalidomide is a good example for this classical route [4]. During a four year period 
thalidomide with the trade name Contergan was originally marketed as a sedative 
especially for pregnant women. After its withdrawal due to its serious teratogenic side 
effects a clinical observation led to its application in erythema nodosum leprosum. 
Similarly, the phosphodiesterase-5 inhibitor sildenafil was in clinical phase for angina, 
but it failed to favourably influence the clinical outcome. However, its side effect later 
led to its approval against erectile dysfunction with a trade name Viagra [4].  
The case of duloxetine is near to what is called a branching development strategy. Eli 
Lilly and Co. originally developed the compound as a serotonin-norepinephrine reuptake 
inhibitor (SNRI) antidepressant later marketed in this indication with the trade name 
Cymbalta. During its development process, based on a mechanistic observation stress 
urinary incontinence (SUI) as a new indication was suggested [4, 11]. This repositioning 
was successful, and duloxetine got approved for SUI with the trade name Yentreve. 
We can regard drug repositioning as a lifecycle management, which led to the new trend 
of early repositioning [12]. The available information during the development process has 
a funnel structure. The information from the early stages is available for a large set of 
compounds, it is general, and it can be used independently of the indication, but it is a 
weak predictor of the clinical outcome. As we proceed, the gathered information will be 
closer to the clinical endpoint, but its specificity for indications will be higher and 
higher [12]. 
In fact the most successful repositioned drugs are based on serendipity, despite the several 
existing systematic approaches [13, 14]. The evidences show that there is need for 
technological intellectual property beside of expert knowledge for a repositioning biotech 
to be successful [13]. An important aspect to understand the difficulty of drug 
repositioning in a classical pharma company is the management mentality against funding 
DOI:10.14753/SE.2018.2060
13 
already failed projects. Another difficulty is that the strategic focus indications are 
specific for a given company, so if we reposition a proprietary molecule it is highly 
probable that there is no clinical expertise available in this new indication [13]. 
Two important types of patent need to be discussed here [4, 13]. The strongest one in the 
sense of protection is the composition of matter (COM) patent, which claims the chemical 
structure of the compound and grants 20 years of protection from the patent application. 
A company needs to protect the compound in development at least before registering it 
as an IND, so at least half of the time spent in the clinical phases is lost from the market 
exclusivity period. Therefore, starting a new clinical development phase after a late 
failure is a risky decision. If a compound fails in Phase III, the company loses too much 
time to start a new trial: a favourable alternative can be a branched development program 
[12, 13]. This extended profiling or early repositioning of a drug candidate can facilitate 
the deeper understanding of the safety and side effect profile of the compound [12, 13].  
The other important type of patent in the field of drug repositioning is the method of use 
(MOU), which claims that the compound can be used to treat a disease. Because the 
original COM patent usually covers a lot of indications, constructing a MOU patent can 
be very difficult. Another way to get a new COM patent is the combination of active 
substances, which forms the base strategy for some of the repositioning biotech 
companies [4]. In case of the orphan diseases, as already mentioned, an extra protection 
is granted by the law [13].  
Another route to improve the productivity of the pharmaceutical pipeline is the 
stratification of the patient population. In a more homogeneous population, where a well-
defined disease state is present, the lack of efficacy type failures can be reduced [15].  In 
several cases diseases known in the past as a uniform group actually have several different 
aetiologies. An excellent example for this is the case of targeted tumour therapies, but the 
disease heterogeneity is observable in several other therapeutic areas like 
neurodegenerative diseases or immunological conditions as well [15-17]. This effect can 
result in apparent inefficacies in clinical trials, as we try to target an ill-defined disease 
instead of the aetiology. 
Drug development for rare or orphan diseases faces with the same complication as 
stratified patient population: the number of patients can be very low. If we can identify a 
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common molecular mechanism between diseases, we develop a drug to that mechanism. 
Another route is drug repositioning: if we can find a drug already registered in a classical 
indication which can be applied in the rare case, we can use it as a candidate. 
Another important factor is the pharmacokinetics related heterogeneity of the subjects. 
Genetic polymorphisms in metabolizing enzymes and transporters can result in 
significant differences of drug metabolism and therefore can cause a lack of efficacy and 
toxicity problems. 
3.2 Overview of Virtual Screening 
To find novel pharmaceutically active compounds with appropriate properties and a 
patentable new structure sometimes millions of candidates should be analysed. If we can 
reduce the number of compounds we need to test in an HTS setting, we can reduce the 
cost of the early phase of the screening program dramatically. Moreover, sometimes the 
in-house dataset does not provide enough chemical diversity, therefore we plan to use 
candidates from external sources or to synthetize new chemistry. In this case, identifying 
a subset of compounds with the highest probability of activity before candidate 
acquisition or synthesis would result in even higher benefits.  
These computational screening methods can be divided into two main classes, target-
based methods and ligand-based methods. In the first case, when the structure of the target 
is known, this information together with the possibly available structure of known target-
ligand complexes can be exploited to guide the search for new active compounds. Most 
often these target structures are available in the form of X-ray crystallography or NMR 
measurements. In the other case, ligand-based methods only use the structural 
information of known active and known inactive compounds and attempts to identify the 
key elements of the structure-activity relationship (SAR) using statistical techniques. In 
this work we are particularly interested in ligand-based techniques. The most important 
categories of these methods are similarity searching, classification and quantitative 
structure-activity relationship (QSAR) modelling. One of the obvious differences of these 
methods is that they provide ordinal, categorical and numerical predictions respectively.  
In its simplest form similarity searching is a basic tool requiring only a single reference 
compound, and returning a list of neighbours from the database, ordered from the most 
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similar to the least similar one. Assuming that the similar property principle holds – two 
compounds with high global similarity have high probability to share the same biological 
activity – the biologically active compounds will be enriched on the top of the ranking. 
The similar property principle is based on the assumption of a smooth structure-activity 
relationship in the chemical space [18, 19]. While pharmacophore analysis and QSAR 
based methods focus on local features of the chemical compound, the similar property 
principle suggests an inherently global viewpoint [18]. This global similarity viewpoint 
assumes a continuous relation between chemical structure and activity: small changes in 
molecular structure cause small changes in activity. Therefore its validity is limited by 
activity cliffs, which can be caused for example by rigid structural elements in the binding 
site of the target. 
A good example for this sudden change of activity in the chemical space is the so called 
„magic methyl effect”, where introducing a single methyl group to a compound can result 
in several fold changes in activity. It is hardly surprising that using purely statistical 
approaches may lead to the misclassification of some samples near to an activity cliff as 
outlier. Without background knowledge, a sudden change of the activity caused by an 
activity cliff and a measurement error cannot be distinguished. In spite of the steric limits 
and well defined pharmacophoric interactions, the structural plasticity of the binding site 
makes it possible that in practice the biological activity is a smooth function of the 
chemical similarity in some regions of the chemical space. These factors also explain the 
strong dependence of the predictive performance on the target protein and on the 
reference compounds in question [18, 20]. Moreover, the performance depends on the 
molecular description method used, and on the different binding modes of similar ligands. 
The above mentioned properties of the chemical space confirm the necessity of data 
fusion to exploit the advantages of the different methods and reference structures. 
To define similarities between compounds we need an appropriate mathematical 
representation of a molecular structure, on which we can apply a function defining the 
similarity metric we want to use. The most straightforward approach to represent a 
chemical compound which meets the requirements described above is to assign a vector 
of numbers to it. This vector is usually called molecular descriptor. Every position in the 
vector - either binary, categorical or continuous – encodes a feature of the compound. If 
the position encodes the occurrence of a substructure, the descriptor is also called 
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molecular fingerprint. The substructure encoded can be two dimensional or three 
dimensional. In theory 3D fingerprints would contain more information than 2D ones, but 
in practice experience shows that most of the time the models based on the former show 
better predictive performance. A possible cause of this is the uncertainty of the relevant 
conformation used for calculating the 3D descriptor. Since the 2D fingerprint can be 
calculated directly from the graph structure of the compound, it is more robust. 
Most of the time the number of possible substructures is enormous, while the vast 
majority of them is missing from a given compound. To handle this situation a function 
with low collision probability – the hash function - is used to map all possible 
substructures to a lower dimensional vector. Another solution is folding, when positions 
in a vector are merged and the new position is set to be active if any of its ancestor was 
active. 
Another problem is that similarity is subjective; as Maggiora et al. said „similarity like 
beauty is more or less in the eye of the beholder” [20]. Or as a machine learning 
practitioner would say, the selection of the similarity metric should depend on the goal 
we would like to reach with modelling; that is, it should be determined in a supervised 
way. 
There is a significant difference between classical similarity searching and machine 
learning methods. This difference is the weighting. Computing similarities between 
actives and candidates and then applying a predefined similarity threshold does not work, 
as the optimal threshold depends on the reference compound [20]. When machine 
learning approaches are used the similarity that we compute will depend on those 
substructures which are relevant for the binding process, and the possible many irrelevant 
common substructures will have a low weight.  
The most popular similarity metric used on binary fingerprints is the Tanimoto or Jaccard 
metric. Its most popular chemoinformatics definition in its vectorial form is the following: 
 
or written with sets (Jaccard definition):  
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The Tanimoto similarity is only used on binary vectors in this work. A possible 
generalization of the Jaccard similarity to non-binary vectors exists for multisets, sets 
where the number of occurrence of a substructure is also taken into account:  
 
There are several application areas for molecular similarities, probably the most famous 
ones are the already mentioned database searching and activity prediction. Molecular 
similarity also has its application in assessing intellectual property positions and diversity 
based library enrichment [20]. In these two latter applications our goal is to maximize 
dissimilarity. 
3.3 Overview of Data fusion 
Molecules have many different types of measurable or computable characteristics from 
as simple ones as elemental composition, 2D structure, 3D structure, and physicochemical 
properties to as complex ones as phenotypic effects in a biological system, which makes 
the available data very heterogeneous. This heterogeneity is especially high in case of 
drug repositioning where we can work with much better characterized compounds. The 
relative importance of these characteristics depends on the scientific question we want to 
answer. The combination of this type of heterogeneous data should be problem specific, 
which imposes a significant mathematical challenge. Even in the prediction of drug action, 
different types of features and different inter-molecular similarity metrics can be 
predictive for different targets. This type of „no free lunch” characteristic, which is 
inherent in nature, makes the task even more challenging. The no free lunch behaviour is 
well known, and mathematically proven in the case of machine learning models [21]. 
What we call data fusion has always been organic chemists' general practice in a smaller 
scale. Let us consider a structure elucidation process based on infrared (IR) spectra, mass 
spectrometry and different multidimensional nuclear magnetic resonance (NMR) 
experiments. These spectroscopic measurements provide information about the different 
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aspects of the unknown compound. IR informs us about functional groups with 
characteristic bands, mass spectrometry about exact molecular mass, and optionally 
fragmentation data. On the other hand, NMR provides a wide range of information from 
local environments of protons, carbon, nitrogen, oxygen, phosphorus, fluorine atoms 
among others, and pairwise bond count distances, or even distances in the three 
dimensional space. All of these fragments of information, even if some of them are highly 
redundant, can be used to deduce the structure of the unknown compound with high 
confidence. In the modern era of big data our need to synthetize information and 
knowledge is still present, we just need computers to understand the relations in this 
enormous volume of data. 
In chemoinformatics, it is very popular to fuse rankings or scores derived by different 
methods based on different information sources. In case of the rank fusion, we order the 
possible candidates (here compounds) and fuse this ranked list to a consensus ranking. 
This process can be interpreted as a special case of quantile normalization, a statistical 
technique often used in expression microarray data analysis [22, 23].  
In an earlier chemical application of data fusion basic min-rank, max-rank or sum-rank 
rules were evaluated on the individual rankings [24]. These rules simply calculate the 
minimum, maximum or average of the given compound's rank in the different lists, and 
reorder them using this new derived score. The sum-rank rule is commonly referred to as 
Borda protocol in information retrieval, which name is used in this work. It is originally 
an election method named after the French mathematician Jean-Charles de Borda. When 
applying this method, each voter creates a full preference list of the candidates, and scores 
them inversely to their preference: gives N point to the first candidate, N-1 to the second, 
and so on. Finally, these scores are summed globally, and the candidate list is ordered 
based on these points.  
If we assume that every scoring function uses only a single reference structure, we can 
identify two cases. Two scoring functions can be different because the underlying 
similarity metric used is different, or because the reference active compound is different. 
The data fusion applied in the former case is called similarity fusion, while in the latter 
case we can talk about group fusion [25, 26]. It is shown by multiple studies that in case 
of similarity fusion sum-rank outperforms min-rank and max-rank, and the average of the 
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individual data source performance [24]. Furthermore, in some of the experiments the 
fused score showed at least as good performance on average as the best individual scoring 
function [24-26]. 
In case of group fusion it is shown that max-score fusion is better than sum-score or sum-
rank [26-28]. Because in this case the underlying similarity metric is unchanged, there is 
no need for the quantile normalization effect of the rank based fusion rules [27]. As the 
naming can be misleading at the first read, at this point it should be noted that min-rank 
is the quantile normalized pair of max-score and max-rank is the pair of min-score. It is 
also shown that to gain from the application of group-fusion query diversity is preferred. 
However, it is true that lower query diversity results in higher predictive performance 
both in the case of the single data source and the fused result. An interesting connection 
is that one-class support vector machines (see details in Section 3.14) can be interpreted 
as a robust hybrid of max-score and weighted sum-score rules, where representatives – 
the so called support vectors – are automatically selected from the reference set. These 
support vectors represent the boundary of the known actives in the chemical space. In our 
experiments we found that query diversity is preferred only to a limit (see Section 6.1). 
The group fusion can be used for scaffold hopping if the fusion strategy is chosen 
correctly. The simplest max-score rule is expected to result in poor retrieval of new 
scaffolds, because all of the retrieved molecules will have a single dominant reference 
molecule, where the similarity is maximal.  
A different type of fusion rule beside the rank and score based rules is the voting fusion 
rule, also called classifier fusion. In this case binary pass-fail votes are aggregated to reach 
consensus prediction. Votes are collected for all candidates and only those candidates are 
selected as active which reached a predefined number of pass votes. This fusion technique 
leads to an increase in precision but a comparable decrease in recall [25, 29, 30]. 
Unfortunately, it is not possible either to identify the best fusion rule and scoring function 
combination independently from the target, but fused scores are usually more robust to 
the change in the task or database than single ones [18, 24, 25]. This shows the real 
persistent nature of the no free lunch property, and motivates the application of problem 
specific fusion rules. A possible solution is the application of a regression-based fusion 
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rule, where the weighting of the different data sources are tuned to get optimal 
performance on the specific task at hand [31].  
Another important decision is how to choose the performance reference for our fusion 
method. We can compare the fusion result to the best individual data source; in this case 
the result is clear if the fusion provides a better result than the reference. A less strict 
reference commonly applied is the average performance of the sources. If our fusion 
result is better than the average, it is still useful because to select a better than average 
single data source we need to validate all sources individually, and we will lose statistical 
power due to the needed validation datasets. 
To increase predictive performance in the case of single reference structure Hert el al. 
introduced a method called turbo similarity searching. They used the nearest neighbours 
of the reference structure as co-reference structures and reached performance 
improvement [32]. They gave a somewhat ad-hoc interpretation of the result in the paper, 
but a quite plausible interpretation of the performance gain is a more general statistical 
phenomenon. The method introduces the local structure of the chemical space into the 
decision process. In that sense the method can be interpreted as a type of machine learning 
method from the positive and unlabelled learning class, and shows strong similarities to 
self-training [33]. For a detailed discussion on the positive and unlabelled learning 
problem see Section 3.15. 
A key assumption in similarity and group fusion is that inactive compounds are more 
diverse than active ones. This assumption makes it highly probable that different metrics 
score active compounds more consistently than the inactive ones. We can formulate the 
independent-and-accurate criteria well known in machine learning as follows: in an ideal 
case we want information sources which produce accurate ranking on active compounds 
and uncorrelated ranking on inactive ones. Another formulation for this criterion in the 
special case of ranking fusion was suggested based on the difference of rank–score 
graphs [34]. 
The literature of target-based methods usually refers to data fusion methods as consensus 
scoring. Ligand poses are evaluated with multiple scoring functions, and then a consensus 
result is computed [29]. Several fusion rules have been applied for consensus scoring 
including sum-rank and min-rank like rules, and robustified versions of them where the 
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worst ranks are dropped before applying the fusion rule. Other approaches use binary 
pass-fail votes computed based on the different scoring functions, or build regression 
models to combine scores. Another interesting direction is the combination of ligand-
based and target-based data sources [35]. 
3.4 Network pharmacology 
Polypharmacology, a property of a compound to be active on more than a single 
biological target, has been regarded as unfavourable by the classical medicinal chemistry. 
Efforts have been made to develop maximally selective compounds, ideally showing high 
affinity only to a single target. This is a rational approach to reduce the chance of side 
effects related to off-targets. Paul Ehlich's concept of „magic bullet”, selectively targeting 
disease causing targets, shaped the landscape of drug design for decades. As the network 
view of complex diseases got widely accepted, the view of pharmacotherapy as 
perturbation of a complex network became more and more dominant [36, 37]. Nowadays, 
the reductionist approach of treating targets as entities standing without biological context 
is more and more criticized. Psychiatric drugs are typical agents with extensive 
polypharmacology on central nervous system (CNS) related targets. For example, 
atypical antipsychotics have activity on a wide range of targets including antagonism on 
various dopamine and serotonin receptors. Beside the experimental evidences that 
inhibition of dopamine action on the D2 receptor seems to be essential for their therapeutic 
value against the positive symptoms of schizophrenia, other targets - especially 5-HT2A - 
are also important [38]. Actions on these targets determine the differential behaviour of 
these agents, like the action against negative symptoms or the risk of dyskinesia. This 
network view can result in a wider range of information sources for in silico methods, 
including side-effects, off-label uses, molecular biological information and gene 
expression (see Table 1). 
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Table 1 - Network levels relevant in the pharmaceutical sciences. 
Network Level Possible information sources 
Disease – Disease Side effect profile, co-morbidity profile 
Compound – Protein Target profile, metabolizing enzyme 
profile 
Protein – Protein Pathway analysis, target identification 
Gene expression Differential expression profiles (e.g.: 
CMAP) 
 
The classical target based assay is not appropriate for designing agents with 
polypharmacology. However, phenotypic screening can be an answer to the problem of 
modern candidate screening, as it starts from the system level state. In these screens 
compounds are tested on disease models to achieve a desirable change in phenotype. The 
downside of this approach is that target deconvolution efforts are needed to figure out the 
precise mechanism of the candidates found with phenotype based screens. 
One class of polypharmacology based therapy can rely on the phenomenon of synthetic 
lethality. Synthetic lethality is a cellular death occurring due to the simultaneous 
perturbation of two or more genes or gene products [36, 39]. These perturbations can be 
caused by genetic change or modification like naturally occurring mutation, knock-out or 
RNA interference experiment; pharmacological modulation, or environmental changes. 
Synthetic lethality can be a particularly important mechanism in cancer therapies, where 
the difference of the tumour cells and the wild-type host cells are in principle 
characterizable by specific mutations resulting in a changed protein-protein interaction 
(PPI) network. This new network can have new lethal targets which are non-essentials in 
the wild-type cells. This approach can be interesting especially in cases where the causal 
mutation is a loss of function mutation which is complicated to reverse, or it is found in 
a gene, whose product is difficult to modulate pharmacologically. Similarly, in case of 
drug combinations where more than one chemical perturbations are applied, the 
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prediction of the resulting effect needs to take into account the network structure. The 
detection of these types of complex interactions demands network based multivariate 
statistical techniques, which can take into account redundancies and synergies between 
variables. The Bayesian network based Bayesian multilevel analysis of relevance (BN-
BMLA) methodology is an ideal candidate for this task (see Section 3.9). 
Designing agents for specific disease cases with known genetic variants also leads us to 
the field of personalized medicine. As in the case of tumour cells, interpersonal variability 
of the protein-protein network can lead to differences in the set of relevant targets. 
Therefore, the knowledge of the patient specific network can help choose a therapy which 
will probably be effective in the case in question counter to the classical therapy effective 
in the general population. 
Synthetic lethality highlights one of the probable reasons why we need compounds with 
polypharmacology: the well-known robustness of the biological systems. As developed 
by evolutionary steps under continuously changing environmental conditions, these 
complex systems need to be robust against most of the single point changes and against 
a wide range of environmental effects. We need network biology based considerations to 
attain stable changes of the phenotype [37, 40]. 
Modulating central protein nodes, hubs, with a really high number of connections, can 
lead to toxicity because of the essentiality of these proteins. Conversely, peripheral nodes 
are probably well buffered, and drugs acting on these targets can have a lack of efficacy 
type problems. It is found that the middle ground, highly connected but not essential 
proteins are good drug targets. According to the network pharmacology paradigm the goal 
is to identify one or more network nodes – target candidates – whose perturbation would 
result in system level changes, and, more importantly, a favourable change in the disease 
related phenotype. 
An interesting new direction is the intentional design of multi-target directed ligands, 
using the already known SARs [16]. One possible option is the design of conjugated 
ligands when two or more already tested bioactive pharmacophores are linked together to 
form a new ligand. This method can result in high molecular weight and ADME problems. 
Another technique is to design a ligand with overlapping pharmacophores which can lead 
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to smaller molecular weight and structural complexity, but at the same time makes the 
design process more complicated. 
The method of selective optimization of side activities (SOSA) can also be used as a route 
to polypharmacology. The main idea of SOSA is to screen a diverse set of existing drugs 
for new activities with the aim of finding a starting point for further optimization, and not 
a candidate for direct repositioning [41]. With this method all starting points will be drug 
like by definition. The optimization goal thereafter will be twofold: on the one hand, to 
increase the new activity of the candidate; and on the other hand, to reduce the old activity. 
In case of optimization for polypharmacology, the original activity can be one of the 
desirable activities. 
Screening methods using gene expression become a universal reductionist approach. The 
proposal of gene expression as lingua franca of different perturbations on a biological 
system had a great impact [42]. The Connectivity Map defines a biological state by a gene 
expression profile, which is clearly a reductionist approach given that the downstream 
state variables like protein and metabolite levels and post translational modifications are 
not included.   
The Connectivity Map contains a database of reference profiles; gene sets ordered by 
differential expressions in a control–treatment setting. Using a query signature, a list of 
differentially expressed genes annotated by the direction of the expression change, the 
reference databased can be searched. The retrieved profiles are then ordered based on a 
gene set enrichment score, called connectivity score. The score can be positive or negative 
depending on the relative direction of the differential expressions. If the directions are the 
same in the query signature and the database profile the connectivity score is positive, but 
if they are reverse, the score is negative. The original work suggests that if a perturbation 
A has negative connectivity score with condition B, then it may reverse the effect of the 
condition. In practice this is true only if a strong linearity assumption of gene expression 
changes holds. 
Chemical compounds, short hairpin RNAs or, more generally, perturbagens can be used 
to treat different cell lines. In the Connectivity Map reference set relatively high 
concentrations (mostly 10uM) and short accumulation times (mostly 6h) were often used. 
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This time is usually not enough for feedback loops to get activated, and to cause changes 
in the expression of the target itself [43]. 
Illustrative examples on histone deacetylase inhibitors (HDACi), oestrogens, 
phenothiazines and natural compounds show that the method can recover structurally 
non-related ligands, can differentiate between agonists and antagonist and can be used for 
target discovery [44]. The usage of disease related profiles from an animal model was 
also demonstrated on the case of connectivity between diet-induced obesity profiles and 
peroxisome proliferator-activated receptor gamma (PPARγ) inhibitors. Two 
demonstrative examples were also given for human samples: Alzheimer's disease and 
dexamethasone resistance in acute lymphoblastic leukaemia [44]. 
A similar connectivity database was also built from differential expression profiles based 
on Gene Expression Omnibus DataSets [45]. A network containing disease and drug 
nodes and edges between them was constructed using profile correlation or using the same 
signature enrichment based method as in Connectivity Map. The set of nodes in the 
network was also extended with the reference profiles from the Connectivity Map. It was 
illustrated that the disease–drug links in this network can be used as hypotheses for drug 
repositioning and side effect discovery; while on the other hand, drug–drug links can be 
useful in target and pathway deconvolution. 
A network based analysis method for differential expression in these chemical 
perturbation experiments discussed above is also suggested [43]. This method uses 
functional protein associations from a database of known and predicted protein-protein 
associations. It is shown that simple differential expression based ranking is not a good 
predictor for target identification, because it relies on feedback mechanisms changing the 
own expression level of the targets. Therefore, a diffusion method is used to distribute 
differential expression based evidences through the network. These evidences are 
diffused through the functional association links, or based on the correlation of the 
neighbourhood structure of the proteins. It is not surprising that this method works best 
on nuclear receptors, which are directly linked to the gene expression level. Galahad, a 
free online service based on this method provides full microarray data processing pipeline 
for drug target identification [46]. It can be used to prioritize candidate targets, predict 
new mode of actions or off-target effects. 
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The network view also changes the way how we see diseases. Contrary to the traditional 
symptom based classification, more and more effort is made to discover the common 
mechanisms, and the co-morbidity structure of diseases. A good illustration for the 
entanglement of disease states is the fact that a naive guilt-by-association based method 
can reach surprising performance [47]. The suggested method is based on the following 
assumption: if two diseases share a drug, another drug for one of the diseases can be 
prioritized as treatment of the other. During the evaluation of the method 12 fold 
enrichment has been detected in clinical trials relative to random drug–indication pairs. 
The similarity of the active ligands on two proteins is a more sophisticated information 
which can be used. The binding site similarity of two proteins can be significantly 
different from their sequence similarity and can be unrelated from their evolutionary 
origin. A common endogenous ligand in a metabolic pathway for example can result in a 
convergent evolution of the binding sites. A similar phenomenon is the existence of 
ionotropic and metabotropic receptors for the same endogenous ligand. Based on this 
observation, a method called the Similarity Ensemble Approach (SEA) was 
developed [48]. SEA assesses protein similarity using 2D fingerprint based similarity of 
their ligands. More precisely it analyses the distribution of pairwise Tanimoto similarity 
scores between ligands of the two proteins with a correction for set size bias. Analysing 
the differences between sequence based and ligand based similarities shows typical 
protein groups with divergent and convergent binding site evolution, furthermore it 
illustrates the current trend of selective ligand design. It has been illustrated that the 
method can be used for the prediction of new primary or side effect related targets even 
between protein families [49].  
An approach with possible application for personalized medicine is also suggested in the 
literature [50]. This method can handle repositioning scenarios and novel molecules as 
well. Using known associations as gold standard for training a classifier to distinguish 
valid associations from random pairs, the method can be seen as a multi-task learning 
method. Because data are only available for valid drug–disease associations, random 
associations are used as a negative set for training. For more details on methods for 
learning from positive and unlabelled samples see Section 3.15. The method uses five 
drug–drug similarities (three out of which are drug target related) and two disease–disease 
similarity metrics to describe the associations. The applied drug–drug similarities cover 
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the chemical and side effect aspects, and the similarities between the drug targets based 
on sequence, PPI network and Gene Ontology (GO) categories. The disease–disease 
phenotype similarities are based on Medical Subject Headings (MeSH) terms and Human 
Phenotype Ontology (HPO) base semantic similarity. An alternative set of disease–
disease similarity based on gene expression signatures was also used. This points to the 
direction of personalized medicine: diseases can be represented with expression profiles, 
therefore a given specific case of the disease can be screened as well. After the application 
of a conservative cross-validation scheme the method reached significant predictive 
performance. A biologically motivated validation technique was also applied based on 
disease–tissue and drug–tissue associations. The hypothesis behind this validation was 
that it is highly probable that a target of a drug should be expressed in the tissue, which 
is relevant in the context of the new indication. 
 The side effect resource (SIDER) developed by Kuhn et al. contains side effect terms 
and frequencies of occurrences based on text mining from public data sources, mainly 
FDA package inserts [51]. For text mining a side effect dictionary based on the Unified 
Medical Language System (UMLS) ontology has been used. As side effects can be 
regarded as phenotypic responses to a given chemical perturbation, they represent 
valuable information for describing biologically active compounds. Placebo controlled 
frequencies have been also extracted for a subset of the drugs. 
It is shown by the same research group, that the set of side effects can be used as a 
predictor for drug-target interaction in the context of drug repositioning [52]. The above 
discussed work of this group, which was one of the main motivations of the repositioning 
related works in our research group, led to a patent application about aprepitant as a 
potential agent in cancer therapies [53]. It is claimed that aprepitant is a non-competitive 
inhibitor of the enzyme thymidylate synthase and inhibits cell proliferation. 
PROMISCUOUS is another online database project; it is a rich information source with 
search and network exploration tools with the purpose of helping drug-repositioning [54]. 
PROMISCUOUS contains four different types of interactions; namely, drug–protein, 
protein–protein, drug–side effects and drug–drug, where protein targets are also mapped 
to KEGG pathways. There is a possibility to search the database by drug, ATC class, side 
effects, targets or KEGG pathways, and to visualize the interaction in a network. The 
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system has a side effect similarity feature, which is able to list drugs based on a high 
number of shared side effects. 
3.5 Evaluating the performance of virtual screening 
First, we illustrate performance measures in a medicinal chemistry context using a small 
example. Let us assume we have 20 unknown compounds, 5 out of which are active COX-
1 inhibitor. The fraction of actives (RP) in this dataset is 25%, which is selected for 
illustrative purposes and unrealistically high in practice. We have three different methods 
which order these compounds based on the chemical structure and further information we 
have. After ordering the compounds, we check the COX-1 inhibitory activity of the 
compounds in vitro, and we get the result on Figure 3. 
 
 
In this example red colour always indicates active compound and blue indicates inactive 
compound. In Figure 3 boxes represent compounds in the order the given method ranked 
them. The question is which method is the best.  
The answer, as always, depends on what we mean by 'the best'. To concentrate on 
performance measures, let us regard these predictors as black boxes, which means there 
is no use of the predictor on its own; we want to evaluate only the predictive performance 
of the models. For instance, we cannot learn new chemistry by inspecting them, or we 
cannot use the models for lead optimization more effectively than just predicting activities 
of analogues. 
If we have limited capacity to test compounds, and we want good candidates for our 
pipeline, how much can we gain? We will apply a threshold τ to define the position in the 
Figure 3 - Output ordering of three hypothetical prioritization methods on 20 
compounds: 5 active (red boxes) and 15 inactive compounds (blue boxes). Predicted 
activity is highest on the left side and lowest on the right side. 
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list above which the compounds are predicted to be active. To measure predictive 
performance we need to define some statistical measures: 
True Positive (TP): Number of compounds our classifier predicted as active out of the 
real active ones. 
False Positive (FP): Number of compounds our classifier predicted as active but which 
actually are inactive. 
True Negative (TN): Number of compounds our classifier predicted as inactive out of the 
real inactive ones. 
False Negative (FN): Number of compounds our classifier predicted as inactive, but 
which actually are active. 
All of these four measures are threshold dependent, therefore we could write them as 
functions as well in the form: TP(τ), FP(τ), TN(τ) and FN(τ) respectively. We will need 
two parameters of the library, which are independent of the model and the applied 
threshold: 
NP (All Positives): The number of active compounds in our library. NP which applies to 
our whole library is usually not known, but it can be known in case of a validation set. 
NN (All negatives): The number of inactive compounds in our library. The sum of NP and 
NN is the size of the library NA, and the ratio of actives can be written as RP = NP/NA. 
As we will see, these numbers will be sufficient to derive all measures we need in a 
contingency table (Table 2).  
 
Table 2 - Contingency table. Table containing all sufficient statistics we need to assess 
performance given a threshold τ. 
 Real active 
(NP) 
Real inactive 
(NN) 
Predicted to be 
active 
True Positive False Positive 
Predicted to be 
inactive 
False Negative True Negative 
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We will use the following derived measures: 
Sensitivity (also called Recall): The fraction of the active compounds that the classifier 
identified successfully. TP / NP 
Specificity: The fraction of the inactive compounds that the classifier excluded 
successfully. TN / NN 
Precision (also called Positive Predictive Value): The fraction of real actives, in the set 
of compounds that the classifier identified as active. TP / (TP + FP)  
For a medicinal chemist, precision has a probably more intuitive form called the 
Enrichment Factor (ER). ER is a normalized form of precision by the fraction of active 
compounds in the whole dataset. It measures the fold of increase in the number of hits, 
which the experimenter can get if instead of choosing random compounds from the library, 
they test compounds predicted by the model. We can write EF proportional to sum of 
weights for all active compounds [55]: 
 
where the weighting for a compound ranked before the threshold is 1, and after the 
threshold is 0: 
 
where ri denotes the rank of the active compound i in the output ordering of the model. 
Let us assume that we have capacity to test 4 compounds, so we will use the methods to 
predict the 4 most likely active compounds (Figure 4). 
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 Actives  
NP = 5 
Inactives 
NN = 15 
Predicted to be 
active: 4 
TP: 2 FP: 2 
Predicted to be 
inactive: 16 
FN: 3 TN: 13 
 
 Actives  
NP = 5 
Inactives 
NN = 15 
Predicted to be 
active: 4 
TP: 3 FP: 1 
Predicted to be 
inactive: 16 
FN: 2 TN: 14 
 
 Actives  
NP = 5 
Inactives 
NN = 15 
Predicted to be 
active: 4 
TP: 1 FP: 3 
Predicted to be 
inactive: 16 
FN: 4 TN: 12 
Figure 4 – Contingency tables and graphical illustration of thresholding for τ = 4 
Based on these contingency tables, we can compute the derived measures (Table 3). 
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Table 3 - Derived measured computed for τ = 4 
 Method 1 Method 2 Method 3 
Sensitivity 0.40 0.60 0.20 
Specificity 0.87 0.94 0.80 
Precision 0.50 0.75 0.25 
Enrichment Factor 2.00 3.00 1.00 
 
For example, in case of Method 1 40% of the actives (two out of five) has been in the 4 
selected compounds, therefore they have been identified successfully, while 87% of the 
inactive compounds are excluded. The ratio of actives in the 4 selected compounds is 
50%, which corresponds to a two fold increase relative to random selection.  We can see 
from Table 3 that the classifier corresponding to Model 2 at the selected threshold 
outperforms the other two classifiers irrespectively of our optimization goal. For example, 
this classifier improves our hit rate by 3 folds. While this classifier is objectively better, 
the same is not true in the level of the methods. Let us choose now a new threshold: we 
can now test 10 compounds (Figure 5). 
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 Actives 
NP = 5 
Inactives 
NN = 15 
Predicted to be 
active: 10 
TP: 5 FP: 5 
Predicted to be 
inactive: 10 
FN: 0 TN: 10  
 
 
 Actives 
NP = 5 
Inactives 
NN = 15 
Predicted  
to be active: 10 
TP: 3  FP: 7 
Predicted  
to be inactive: 10 
FN: 2 TN: 8 
 
 Actives 
NP = 5 
Inactives 
NN = 15 
Predicted  
to be active: 10 
TP: 1 FP: 9 
Predicted  
to be inactive: 10 
FN: 4 TN: 6 
Figure 5 - Contingency tables and graphical illustration of thresholding for τ =10 
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The computed derived measures are shown in Table 4. 
Table 4 - Derived measures computed for τ = 10 
 Method 1 Method 2 Method 3 
Sensitivity 1.00 0.60 0.20 
Specificity 0.67 0.53 0.40 
Precision 0.50 0.30 0.10 
Enrichment Factor 2.00 1.36 0.40 
 
With this threshold the classifier corresponding to Model 1 outperforms the other two 
classifiers according to all measures. It is clear that the performance of a model we want 
to use for classification will depend on the threshold, but will not depend on the ordering 
of the compound above or below that threshold. We can plot this performance for all 
possible thresholds using a tool called Receiver Operating Characteristic or ROC curve. 
As a convention, we plot the sensitivity with respect to 1-specificity for all threshold levels 
(Figure 6). 
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In some cases we are interested in the predictive performance of the models in a threshold 
independent way. One measure to use in this case is the area under the ROC curve (AUC). 
The AUC value has a very intuitive interpretation: it gives the probability of ranking an 
active compound higher than an inactive one if the inactive-active pair in question is 
drawn uniformly at random. This interpretation relies on the connection between AUC 
and the Mann-Whitney-Wilcoxon statistics [56]. 
We can see that according to the AUC measure, Method 1 is better than Method 2, which 
is better than Method 3. We can also realize that Method 3 would be a bit better if we 
inverted its ordering. The truth is that the ordering for Method 3 was generated randomly; 
and because of the small number of entities, its AUC value can randomly deviate from 
the totally random model. If we had a huge number of entities, a random model would be 
a diagonal line with AUC = 0.5. To better understand the apparently controversial 
statements about Model 1 and Model 2, let us examine the ROC plots of them together 
(Figure 7, left). 
Figure 6 - Receiver Operating Characteristics (ROC) curve of the three different 
prioritization methods. Every coloured dot corresponds to an active (red) or inactive 
(blue) compound in the ordered sequence. 
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The green ROC curve corresponds to Method 1, and the brown one to Method 2. The 
green and brown shaded area corresponds to the superiority of Method 1 and 2 
respectively. The AUC metric weights the two sub-area equally, Model 1 therefore has 
higher AUC value. 
It can be shown that we can write AUC in the following form: 
where ri denotes the rank of the active compound i in the output of the model. From this 
equation we can see that AUC is a linear transformation of the sum of a weighting, where 
the weights are: 
If our chemical library contains several millions of compounds, but we have a limited 
testing capacity for testing only the top hits – which is the case in practice - , we are 
usually not interested in the performance after the top hits i.e. in the brown area. We want 
to weight the early part higher, and only invest time and money in more measurement, if 
it is really worth it. In this case we are facing the so called early recognition problem. An 
Figure 7 - Comparison of the Receiver Operating Characteristics (ROC) (left) and the 
Concentrated ROC curves (right) of Method 1 and Method 2. The green area represents 
the superiority of Method 2 in classification tasks using small threshold value, the 
brown area represents the superiority of Method 1 in case of high threshold values. 
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intuitive way to do it is to transform the horizontal axis of the ROC curve in such a way, 
that the area elements in the early part of the curve will be magnified, and in the late part 
they will be compressed. In a more formal way, we apply a continuous compression 
function f to 1-specificity, which maps the [0,1] interval to itself, f : [0,1] → [0,1]. An 
illustration is shown on Figure 7 (right), where we can see that the green area in the low 
end of the 1-specificity axis is now magnified, while the brown area at the high end is 
compressed. This type of transformation reflects our preference in the early recognition 
problem and can be achieved by a concave compression function, which has a derivative 
higher than 1 for low values, and lower than 1 for high values. This measure is called the 
concentrated ROC (CROC) [57]. A well-behaving compression function, which we will 
use in this work is the exponential compression:  
 
This function has a parameter α, which defines how early is the part we want to focus on.
  
 A very similar measure can be derived also form the probability theory point of view, 
called Boltzmann-Enhanced Discrimination of ROC (BEDROC) [55]. If we enforce that 
our weighting corresponds to a proper probability density function f(x), than we can 
interpret our weighted sum in the continuous limit: 
as an expected value, which have a similar probabilistic interpretation to AUC given that 
αNP/NN << 1 holds, which is usually the case in virtual screening, and is the case in our 
experiments as well. 
Similarly to the case of AUC, we need to transform this rank average based metric to get 
a metric which have values between 0 and 1: 
 
It is important to note that BEDROC is not a measure which tells if our model is better 
than a random model or not. It tells if our model is better than a reference enrichment, we 
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selected that way that it is sufficient to reach our virtual screening goal. We can however, 
analytically compute the BEDROC score of a model ranking the actives corresponding 
to a uniform distribution: 
which is with a good approximation 0.05 for α = 20.0.  
In case of the sensitivity, precision or EF, a hard threshold is applied, which means every 
active compound found higher than the threshold level is counted with equal weight, and 
every compound under this level is ignored – weighted by zero. In case of AUC all active 
ranks have equal weight. The measures like CROC or BEDROC can be interpreted as a 
trade-off between these two extremes: a decreasing weighting function - in our case an 
exponential - is applied to the ranking. These measures can take into account the early 
discovery requirement, but they are more stable than hard thresholded methods. Because 
we want to apply our method not exactly on the compound library we used for testing, 
but possibly many similar libraries, we need a robust evaluation, which does not depend 
strongly on small perturbations of the order. 
3.6 Probabilistic graphical models in the Bayesian statistical 
framework 
Probabilistic Graphical Models (PGMs) are standard representations of complex 
probabilistic models, as they allow the use of the underlying independencies in both 
model specification, learning and inference. A particularly popular subclass of PGMs are 
the Bayesian networks (BNs), which allow the specification of local dependencies. 
Another universal framework used in the thesis is the Bayesian statistical framework. In 
the following sections an overview will be given about the basics of that methodology in 
the hope that the name will gain its correct semantics. 
3.7 Bayesian framework 
The Bayesian statistical framework is gaining wider and wider acceptance as a principled 
approach to cope with uncertainty with respect to a priori knowledge, statistical models 
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and predictions [58]. In the Bayesian framework we do not assume that we will be able 
to build „the correct model” based on a limited number of observations, therefore we use 
all possible models weighted by their probability of correctness; the probability 
distribution of all models. In practice we calculate with a limited set of probable models 
because of the computational limitations. As the Bayes-theorem states, after which the 
framework is named: 
 
Where P(M|D) denotes the above mentioned probability distribution of all models M 
given the observed data D, called the posterior distribution. P(D|M) is the data likelihood, 
the probability that we observe the data we have, given that M is the correct model. P(M) 
represents the a priori correctness assumption of the models. P(D) is the marginal 
likelihood. As it does not depend on M it is only a normalization constant of the 
probability density over the models. From now on, we can use this P(M|D) distribution 
for prediction, or to gain understanding of the dependency structure between the variables 
in the domain. We can infer the a posteriori distribution of a variable V using 
marginalization, i.e. summing the distributions according to each model, weighted by the 
model probability:  
 
Similarly, we can compute marginals not only to get the distribution of a variable or set 
of variables in the domain, but to get the distribution of some properties of the model as 
well. Let f(M) denote a feature of a model, like the existence of some kind of statistical 
dependence between two variables. Then we can compute its a posteriori probability by: 
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3.8 Bayesian networks 
Bayesian networks are graphical models with directed acyclic graph (DAG) structures. 
They are composed of a set of vertices (representing random variables) and directed edges 
between them. Being a DAG they do not have directed circles, which statement is 
equivalent to the fact that at least one ordering of the variables exists in which edges are 
only directed from variables to other variables forward in the ordering. Those variables 
from which variable V has incoming edges are called the parents of V. Here we are 
interested only in the structure of the Bayesian networks; we will ask questions related to 
the existence of some edges and neighbourhood relations. These relations encode direct 
relevances of genetic polymorphisms to measured pharmacokinetic parameters of drugs. 
However, to provide an insight into how the probabilities of the possible models are 
constructed we should take into account that there is an other layer of specification. Every 
vertex has a description of the conditional probability of the variable it corresponds to, 
given the value of its parents. In general, this description can be any function mapping 
from the values of the parents to a distribution of the child variable. However, in the case 
of discrete variables a tabular representation is usually used. To illustrate the concept of 
these local probability models on an example, let us consider the local structure on Figure 
8. From the conditional probability table we can read that if all relevant single nucleotide 
polymorphisms (SNP) are absent, the probability of measuring a high Area Under the 
time plasma concentration Curve value is 0.5. If the other SNPs are absent, SNP1 
increases the odds of a high AUC by 50%, SNP2 by more than two folds and the two 
together by 9 folds.  
Figure 8 - Local probability structure of a variable and its parents. 
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Every variable from which we can go to the variable V by stepping through edges in the 
direction corresponding to its orientation are said to be an ancestor of V. It can be seen 
that every variable is independent of these ancestors if we know the value of their direct 
parents. 
   
In the example of Figure 9 the parent of the Inhib variable is only the Level variable, 
which means that according to that model, if we know the active substance concentration 
in the tissue we are interested in, the dose of the drug or the CYP enzyme activity gives 
no more information about the potential inhibition of the target. This is true only in the 
case of ancestors. However, if we know the value of the Dose and CYP it is still possible 
that we can gain extra knowledge about the concentration of the active substance by 
measuring the inhibition. To rule out or isolate all effects, we need to know the values of 
all variables in the Markov blanket of our variable. The Markov blanket of a variable 
contains its parents, its children, and the other parents of its children. Two of these three 
cases was previously discussed. Let us assume that the mechanism of our hypothetical 
drug is a competitive antagonist. In that case the inhibition is also influenced by the level 
of an agonist in the tissue, because the agonist can overcompete the inhibitor in the 
binding site [59]. In Bayesian network terms we have a new parent, let us call it Agonist, 
of the Inhib variable. Now the knowledge of this Agonist concentration can be important 
to infer the distribution of the Level variable from the inhibition. 
Figure 9 - A simplified illustrative Bayesian network of a drug action. The administered 
dose (Dose) and the activity of the relevant CYP450 enzymes (CYP) directly influence 
the level of the active substance (Level) in the tissue of interest, given that no other 
variable is known. This structure does not state that these are the only influencing 
variables, neither that there is no other intermediate variable, like the plasma level of 
the drug in the chain. 
DOI:10.14753/SE.2018.2060
42 
3.9 Bayesian Multilevel Analysis of Relevance 
The Bayesian network based Bayesian multilevel analysis of relevance (BN-BMLA) 
provides an overview of multivariate strong relevance relations, including the option of 
multiple target variables in a multi-task setting. The BN-BMLA uses hierarchical, 
systematically linked levels of representations, such as Markov Blanket Memberships 
(MBMs), Markov Blanket Sets (MBSs), and their subsets (k-MBSs). The method was 
applied in a wide range of bioinformatics problems including genetic association analysis 
[60-64].  
Using the marginalization formula for model properties, we can determine the probability 
of some features in the Bayesian network even if we do not have enough data to determine 
the complete structure.  
A simple f(M) function is used to discover edges. The value of this function is 1 if there 
is directed edge from variable A to variable B, and zero otherwise. Another feature 
function used in this work is the MBM function. The MBM function is 1 if variable A is 
in the Markov blanket of variable B and zero otherwise.  
There is a possibility to calculate edge or MBM features to a set of target variables. In 
that case the value of the function is one, if there is an edge from variable A pointing to 
any variable in the predefined set of target variables, or analogously if A is in the Markov 
blanket of at least one variable of the target set. 
There are several other possibilities, but they are not relevant to this work and they are 
discussed in detail in a book chapter published by the research group at the Technical 
University [65].   
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3.10 Machine Learning methods 
In the chemoinformatics literature the main distinctive feature of machine learning 
methods relative to similarity searching methods is the use of the inactive compound set 
[25]. Here we assume that the discussed methods are black boxes; we are only interested 
in predictive performance and not in interpretation. The machine learning community 
defines itself in a broader sense, e.g. also including methods using only positive labels 
with the goal of learning their weighting. In this work the latter convention is used, 
therefore we discuss here one-class methods, and semi-supervised learning methods in 
the extreme case where only positive samples are available. 
3.11 Linear methods for quantitative prediction 
In regression setting our goal is to build a quantitative model of one or more outcome 
variables using features also called independent or explanatory variables or covariates. In 
chemoinformatics the main applications for regression models is the field of quantitative 
structure-activity relationship modelling (QSAR).  For the discussion of this setting, let 
us assume that the features are organized in an N-by-F matrix X where a row corresponds 
to a sample – here compound – and a column corresponds to a feature. Furthermore let 
us organize all outcome variables to an N-by-M matrix Y, where a row corresponds to a 
sample and a column to an outcome variable. See the illustration on Figure 10. In the 
following discussion - if otherwise not specified - we will work with a single outcome 
(univariate regression). In this case Y is a column vector. 
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Ordinary Least Squares (OLS) is the simplest form of regression methods, which can be 
used to predict compound activities. The name comes from the fact that the method 
minimizes the squared error between the prediction and the known outcome: 
 
 
where β is a vector of model parameters, interpreted as weights on the elements of the 
feature set.  The vector xi is a row of the matrix X corresponding to sample i, and yi is the 
value of the outcome variable corresponding to sample i. 
It can be shown that the β for which the above error term is minimal can be calculated as: 
where the expression multiplying y is called the Moore-Penrose pseudoinverse of X. If 
two features are linearly dependent – they differ only by a linear transformation plus a 
small deviation term – exchanging and transforming the two β values will result in similar 
predictions. From the other way around, a small change in y would result in a huge change 
in some β values. In mathematical terms the condition number of the matrix will be large. 
Even if the problem is numerically stable, models with a high dimensional feature set 
Figure 10 - The structure of a linear regression problem in its general multivariate 
form: X is a sample by feature matrix containing the samples of the covariates, Y is the 
outcome matrix, and β is an outcome by feature weight matrix, containing the model 
parameters. As a convention we add a feature which is always one, and the β 
corresponding to that feature is the bias of the model. 
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trained on a small number of training samples can have suboptimal performance. See the 
topic of over-fitting discussed in chapter 3.16. We can ameliorate these problems if we 
introduce a constraint to restrict the space of possible models, often called regularization. 
One possible way is to reduce the actual dimensionality of the feature set by Principal 
Component Analysis (PCA). PCA will find new derived features which are uncorrelated. 
It can be interpreted as finding a transformation of the coordinate system to minimize 
correlation between the new variables (see Figure 11). In this case feature 1 and 2 are 
nearly linearly dependent, which would cause numerical instabilities during the 
computation of the Moore-Penrose pseudoinverse. On the other hand, the principal 
component corresponding to the largest variance (PC1) and the second principal 
component (PC2) are totally independent, and PC2, which corresponds to the deviation 
from the linear dependence, has small variance. If the two features were perfectly 
dependent, PC2 would have zero variance. More formally PCA finds two matrices U and 
V satisfying 
 
where U is a sample-by-principal component matrix, called the score matrix, and V is a 
feature-by-principal component matrix called the loading matrix. The rows of U, or 
simply scores, describe the samples in the new space, as plotted on Figure 11. The rows 
of V, or loadings, however, define the transformation from the original to the new feature 
space. 
The technique called Principal Component Regression (PCR) is the sequential 
composition of a PCA step on the features followed by an OLS regression. In this case 
we use only the principal components with the highest variance to make predictions, by 
using the truncated scores as features in OLS. In some cases, however, a principal 
component with lower variance can have equal or even higher importance. This problem 
arises from the fact that the creation and selection of the principal components do not 
depend on the outcome value y; they are selected an unsupervised way.   
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The most popular method applied in chemometrics is the Partial Least Squares (PLS) 
regression. In PLS the selection of the latent variables is a supervised procedure. The 
method projects the features and the prediction target or targets to new spaces with 
constrained dimensionality [66]: 
with the optimization criteria to maximize the covariance between these derived variables: 
Having these representations, the method finds a regression model between these two 
spaces: 
 
Because Ti and Ui are corresponding latent variables with the highest covariance, this 
regression problem falls back to independent univariate problems: the D matrix we search 
for is diagonal. 
As the OLS can be interpreted as maximization of the correlation, while the PCR selects 
latent variables according to the maximal variance criterion, PLS is a trade-off between 
these two cases [67].  
 The more general case of PLS briefly discussed above is called the PLS2, which can 
regress for several outcome variables together. This can help to improve predictions 
compared to building separate regression models. This principle is called multi-task 
learning in the machine learning literature [68]. We will use the same effect in matrix 
Figure 11 - Illustration of Principal Component Analysis (PCA) on the case 
of two strongly dependent features. 
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factorization models (see Section 3.17). If the prediction of only one outcome is needed, 
the PLS algorithm simplifies to a variant called PLS1 [69]. 
3.12 Basics of kernel methods 
All of the techniques discussed above are linear, which means a given feature can have 
only an additive effect to the prediction. In some cases a better prediction can be made if 
we take into account their nonlinear effects and the interactions between different features. 
The easiest way to achieve this goal is to derive nonlinear combinations of the original 
covariates and use them in the regression procedure. A modern „off the shelf” method to 
derive a nonlinear counterpart for a linear method while preserving its favourable 
properties is kernelization. In this case we use the observation that the product XTX and 
the product XXT contain the same information for modelling for a given sample by feature 
matrix X. While the size of the square matrix XTX is the number of features and the size 
of XXT is the number of samples, the rank of the two matrices is the same. In the case 
where we have a very high dimensional feature set for moderate amount of samples using 
the later representation is more economical. This is the case when we use chemical 
fingerprints for approved drugs, or we derive a large number of nonlinear interactions of 
features. It is important to note, however, that this trick alone will not prevent the 
problems arising from the high dimensional feature set discussed above. We need to apply 
regularization to address this problem. The simplest illustrative case of the kernel trick is 
the kernelization of the ridge regression (a regularized form of Ordinary Least 
Squares) [70]: 
 
As β is a vector with the size corresponding to the number of features, we can define it as 
a function of a new set of variables α with a size corresponding to the number of 
compounds as:  
 
Substituting back, and applying the Woodbury matrix identity for positive semidefinite 
matrices we get [71]:  
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And to compute the prediction for a new input x, we need to calculate: 
 
On this point we can substitute X by a matrix Φ which is derived from the original features 
by nonlinear transformation Φ = Φ(X). As there is no X outside of an inner product we 
can use K = ΦΦT everywhere. With the kernel trick we can even use an infinite number 
of features if we can directly compute the elements of K, which is always a finite sized 
sample-by-sample matrix (Figure 12). This matrix is called kernel matrix, and the direct 
mapping from the input space to the elements of K is called the kernel function k(xi,xj). 
A similarity relation discussed in the introduction, to form a valid kernel function, needs 
to meet some mild criteria. Because K is a symmetric matrix in the form ΦΦT, the matrix 
calculated with the given similarity relation should be symmetric as well, and it should 
be factorizable in this form.  
According to Mercer's theorem K is a valid kernel if it is symmetric and positive-
semidefinite, that is 
 
 
Figure 12 - Illustration of the kernelization. Using the kernel function k(xi,xj) we can 
have a direct mapping from the input space to kernel space even if the dimensionality of 
our feature space is extremely high. 
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For an illustration, let us use the following kernel function: 
 
It can be shown using the original form of Mercer's theorem that this function is a valid 
kernel function (for the theorem and its application, see detailed description in [72]). To 
illustrate the kernel trick instead, let us expand kernel function above as 
 
from which we can read the feature map Φ: 
The generalization of this kernel for a general exponent d, is called the polynomial kernel. 
Another, probably the most frequently used kernel in the machine learning literature is 
the radial basis function (RBF) kernel has the form 
It can be shown using Taylor-expansion that this kernel corresponds to an infinite 
dimensional feature space: 
As the above equation shows, all elementwise powers of x are included in the feature set, 
but the multiplier decreases strongly with increasing k. 
3.13 Data fusion with kernel methods 
To understand the complex nature of small molecule–target interaction, we need to use 
several type of data sources including chemical structure, mechanism, known targets, 
gene expression, known phenotypic effects; and integrate the information content of these 
sources. The different possible representation of these type of data – like different 
chemical fingerprints for the chemical structure - , and the diversity of the similarity 
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relations make the number of possible combinations even higher. Similarly to genomics, 
the data fusion in chemoinformatics and chemogenomics becoming more and more 
important [73].  
It is practical to divide data integration methods into three categories, namely early, 
intermediate and late integration methods [73]. In case of early integration the feature 
vectors from different information sources are concatenated to a single vector, and the 
modelling procedure uses this as an input. If the model takes into account the correlation 
between the features, the model will use any interaction between features even between 
sources.  
In case of intermediate fusion, the similarities of the entities are combined – usually added 
up - to form a fused similarity matrix. It is, therefore, called as kernel combination. In this 
case the between-source correlations are not taken into account. We generally assume 
that the within-source correlations are more important, therefore we may want to restrict 
the descriptive power of our model this way. The similarity of this motivation to the one 
behind dropout, a widely used technique in modern machine learning, would be worth 
further investigation [74].   
In case of late fusion, separate models are trained based on the different data sources, and 
the decisions of the models are fused. Two possible fusion options are the score fusion, 
when the output of the models are directly combined, and the rank fusion. As we already 
discussed in the case of virtual screening, if we reduce our scores to ranks and then we 
fuse the ranked lists to a consensus ranking, we can combine outputs with significantly 
different score distributions. 
Multiple Kernel Learning (MKL) is a commonly used technique for data integration, 
which depends on the application of the kernel trick. As an intermediate fusion technique, 
MKL depends on the linear combination of kernels:  
 
Here Kk is a kernel derived from the information source k, and dk is a corresponding 
information source weighting which we want to determine during the model building. An 
intuitive way to think about the optimization of the data source weights is that we want 
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to create a combined similarity metric, which makes our query compounds as similar to 
each other as possible, while in the same time make the separation from the other class, 
or from the origin in case of one-class problem, possible. 
We will follow the Lp-MKL formulation [75]. In case of a two-class classification 
problem the non-kernelized optimization objective, also called the primal objective, is: 
 
The objective contains three clearly identifiable contributions, namely the regularization 
of the model parameters, the classification error, and the regularization of the kernel 
weights. As the inequality constraint shows, the problem is equivalent to classifying in a 
concatenated feature space contrary to the early fusion, where we apply concatenation in 
the input space. Following the tedious derivation of Sun et al. we get the kernelized or 
dual objective as: 
3.14 One-class Support Vector Machines 
In its original form one-class SVM aims to identify a region of the input space where 
most of the training examples lie, or more precisely: to identify a function f(x) which has 
a definite positive value f(x) ≥ 1 in the region where a given (1 - ν) portion of the 
probability mass lies. In our application we will take advantage of the smoothness of f(x) 
to prioritize the points, the candidate drugs, in the input space. 
Let the training set be  
 
Using the nonlinear transformation Φ we map the training samples to the feature space, 
where we search for the solution as the form:  
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where the optimization goal is to make f(x) positive for all training samples if it is possible, 
given some regularization constraint. The problem is equivalent to finding a separating 
hyperplane between the training samples and the origin in the feature space.  
 
It can be shown that we can write f(x) in the following form:  
 
where some of the α values will be zero. The support vectors – training examples with 
non-zero α values - will lie on the boundary of the set, and will give the ranking a max-
score like behaviour, as pointed out in Section 3.3. It is also clear that ρ is only an additive 
constant, therefore irrelevant in the ranking case. 
For a similarity metric S for which S(xi,xj) ≥ 0 and S(xi,xi) = 1, the points lie in a 
hypersphere, and also in the same orthant. For illustration in the two dimensional case 
see Figure 13.  
 
 
Figure 13 - Structure of the feature space in case of a normalized similarity metric 
(left), and the example of the prioritization using the separating hyperplane between the 
training compounds (red dots) and the origin (right). 
DOI:10.14753/SE.2018.2060
53 
A multiple kernel version of the one-class SVM can be derived analogously to the two-
class classification case discussed above, from the primal optimization problem [10]:  
 
Leading to a prioritization score: 
 
3.15 Semi-supervised and Positive and Unlabelled Learning 
The SVM models provide good predictive performance [76], but there is space for 
improvement. Like in the case of similarity searching, performance can be improved by 
introducing the information of the input distribution, even if this information lacks labels 
or known outcome values. In machine learning, when a method solves a supervised 
learning task utilizing also the unlabelled examples available is called semi-supervise 
learning. An extreme case of semi-supervised learning when only positive labels are 
available is called positive and unlabelled (PU) learning [77]. This means that in our case 
only active compounds are labelled for an indication, every unlabelled compound can be 
an undiscovered active one, or an inactive. 
The two most well-known semi-supervised learning metaheuristics are self-training and 
co-training. In case of self-training a classifier is trained on the labelled dataset, and then 
prediction is computed for all unlabelled samples. In the further iterations highly 
confident predictions from the previous iteration are added to the real labelled set, and 
the classifier is re-trained [33]. An application of this metaheuristic in chemoinformatics 
is turbo similarity searching [32]. The main drawback of this method is that a false 
prediction can be self-reinforcing. Co-training is a similar method using two different 
classifiers training each other with highly confident predictions. 
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We can view the iterative application of a prioritization method by a human expert as a 
kind of semi-supervised learning assisted with weak evidences or expert knowledge [14]. 
In this scenario a prioritization framework is used to rank chemical compounds, and then 
a human expert selects some of the high ranked candidates into a query set in the next 
iteration. 
 
In case of PU learning if the assumption holds that the missing labels are probably 
unobserved negative labels, we can label a random set as negative. We should be careful, 
however, if we would like to predict new positive cases. 
An illustration of the semi-supervised learning concept is shown on Figure 14. Based on 
our a priori assumption about the distribution conditioned on the label, we can use the 
empirical input data distribution to choose a better classification model. 
Figure 14 - The effect of the utilization of information about the unlabelled samples to 
the decision boundaries of the models. Two class supervised learning task (a) versus 
semi-supervised classification (b), and one-class learning (c) versus PU learning (d). 
Placing the decision boundary the way that it corresponding to our structural 
assumption of the input distribution can lead to an increase in model performance. For 
example this illustration relies on the assumption that our class is compact. 
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3.16 Generalization error and cross validation 
Generalization ability is an important property of a prediction method because we want 
to use our models in new chemical libraries. If a dictionary of known input–output pairs 
is used as a classifier, it is obvious that the performance on this original training dataset 
will be perfect, given that our training data is perfect. For example, a dictionary-based 
QSAR method would just search for the given chemical structure in the dictionary, and 
output its measured activity. It is easy to see that this type of method is totally useless to 
predict new chemical series. This type of non-flexible behaviour is called overfitting.  
Cross-validation is a model validation technique for assessing future performance on 
independent datasets [78].  To avoid overfitting, we can split our dataset to a training set, 
and a non-overlapping test set. The latter is not used in model building, and it is only used 
to compare the prediction of the model with the measurement values. One of the most 
common methods is n-fold cross validation. In that case we divide our dataset to n equal 
sized folds, and use one of them as test set, and the rest as training set. We build the model 
with the n possible training sets separately, and evaluate it with the corresponding test set. 
Using the evaluation metrics we can compute statistics like mean performance, or assess 
the statistical significance of the performance differences. The illustration of n-fold cross 
validation is shown on Figure 15. 
A simpler to implement version is bootstrap cross-validation when we just sample a 
portion of the samples to the test set, and train the model on the rest of the data, and repeat 
Figure 15 - Illustration of 5-fold cross-validation. The dataset is partitioned to five 
parts four out of which is always used as training set and one as a test set. 
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it several times. In this case the variability of the result can be higher because the test sets 
may overlap, so more repeats need to be calculated to reach the same statistical power. 
If the model building has hyperparameters, like ν or C in case of SVM, or the number of 
layers in case of a neural networks, we need to tune these hyperparameters. If we want to 
assess the predictive accuracy on an unrelated dataset we cannot do it by just optimizing 
the test set performance. If we did it, the hyperparameters would be tuned specifically to 
reach good performance on the test set and then we would overestimate the generalization 
performance. Therefore we need to use nested cross-validation. If we are only interested 
to compare different parametrizations or different methods, but we do not want to claim 
a quantitative measure of accuracy in a practical situation, we do not need external folds. 
In nested cross-validation (see Figure 16) we partition the dataset to n outer folds, one out 
of which is used as test set for measuring the performance. The training set is then 
partitioned to m inner folds, one out of which is used for test set during the hyperparameter 
tuning often called validation set, and the others as training set.  
3.17 Macau: Bayesian Multi-relational Factorization  
As it is discussed above, if we do not have enough samples to properly identify a model, 
we should determine the a posteriori distribution of the models instead (Section 3.7). In 
the Bayesian framework we can control model complexity through the prior by simply 
Figure 16 - Illustration of 3x3-fold nested cross-validation. The dataset is partitioned to 
three equal parts two out of which form the outer training set in every iteration. This set 
is now partitioned again to three equal parts, and analogously an inner training set, 
and a validation set is formed. 
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making P(M) small for complex models and large for simple ones. However, we can still 
use other regularization techniques, like dimensionality reduction. Macau is an example 
for this as a Bayesian matrix factorization method for large scale incomplete matrices 
with high dimensional side information. Macau was developed in the STADIUS 
bioinformatics research group at KU Leuven with my participation. In that project I was 
responsible for model specification and for evaluation in pharmaceutical applications. It 
is a general tool that is designed with the special requirements of compound-protein 
interaction prediction task in mind. The so called side information is composed of 
additional features for rows and columns. If the rows of the matrix correspond to chemical 
compounds, side information can be the set of chemical fingerprints. The likelihood of 
the observations P(D|M) have the following form in this specific case:  
 
where U and V variables have their own prior probability, corresponding to the general 
term P(M). The rows and columns of Y can be regarded as entities like drugs and 
indications, and the matrix encodes relations between them. These entities have their own 
representations as a form of the vectors ui and vj. Every entity, like every compound or 
indication category, has its own descriptor vector with the length of K, where K is a small 
number relative to the size of the matrix. Therefore, we limit the number of free variables 
from N x M to N x K + M x K, where K << N,M. 
Macau has a hierarchical structure, and can be described with a graphical model, which 
is similar to the Bayesian networks discussed before (see Figure 17) [79, 80]. In the 
following discussion the precision of the observations (α) is assumed to be known a priori, 
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but in a more general form of the model it can have a Gamma distribution as non-
informative prior. 
The model can be defined by giving the local probability models for every variable 
similarly as P(Y|U,V,α) was given above. As the model is perfectly symmetric, we will 
give the formula only for one of the variables. In the second level the prior of the latent 
variables is defined as: 
 
As xi and xj are observed variables, in the third level we are left with two vectors of mean 
(µu, µv), two precision matrices (Λu and Λv) and two link matrices (βu and βv). The 
speciality of Macau is the proposed scale invariant prior over the link matrices: 
 
where • denotes the Kronecker product operation [81]. This prior is invariant to the scale 
of the latent variables. The determination of the probability distribution of the link matrix 
βu can be regarded as solving a multivariate regression problem (see Section 3.11) in a 
Bayesian context, when our feature matrix is X, and our outcome matrix is V. As V is a 
latent variable and not an observed variable, our regression is “shooting a moving target”, 
therefore the introduction of an adaptive self-adjusting prior was necessary. The prior 
Figure 17 – Probabilistic graphical model of Macau. The graph shows the hierarchical 
structure of the model: the prior of ui and vj depend on the row and column side 
information xi and zi respectively, and link matrices βu and βv are learned for the row 
and column side information. All unobserved -white- variables have their own priors. 
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over Λu and µu is a standard normal-Wishart distribution. Only one pair of variable is left 
for the fourth level: λβu and λβv. Their a priori distribution is the Gamma distribution. 
We can use the independence relations encoded in the graphical model to determine the 
distributions of the variables. For example, if we knew the value of all variables in the 
Markov blanket of ui (xi, βu, µu, Λu and Yij and vj) we could compute the distribution of ui. 
As we do not know the values of these variables, we use a Monte Carlo method called 
Gibbs-sampling to draw samples from the joint probability distribution of the 
variables [82]. 
  
DOI:10.14753/SE.2018.2060
60 
4 Objectives 
The objectives of my doctoral thesis are:  
 To develop a novel data fusion method for the prediction of the biological effects 
of small-molecular drugs by integrating heterogeneous information sources. 
 To apply the data fusion method for finding Parkinson's disease related drugs, and 
to evaluate the ability of this method to enhance drug discovery, especially drug 
repositioning. 
 To develop and evaluate a novel matrix factorization based method capable of 
predicting multiple activities simultaneously, and to compare it with a single 
target baseline method. 
 To adapt and apply a novel Bayesian multivariate statistical technique to identify 
genetic variants predictive of the interpersonal variability of methotrexate 
pharmacokinetics at high dose levels. 
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5 Methods 
5.1 Information sources 
At the start of the research information sources describing compounds were constructed: 
Molecular Access Keys (MACCS); molecular connectivity, shape and electrotopological 
fingerprint (MOLCONN-Z); 3D pharmacophore based fingerprint; side effect 
occurrences and frequencies; and known drug-target interactions. We define the vector 
representation of the compounds for each information source. Also similarity metrics was 
identified to compute pairwise similarity kernels from the features for the methods 
requiring similarities. The Tanimoto similarity was used for every information source 
with binary features, whereas the cosine similarity was applied for sources based on real 
valued features. 
The basic summary provided below describes the source of the data, the software version 
used to generate the features and the number of drugs for which the given type of 
information is available. It also shows the mean and median value of all pairwise 
similarities and the histogram of all pairwise similarities, which gives an image of the 
distribution of similarity relations in the space defined by the given features.  
Two main versions of these information sources were used during the work: the first 
version relies on the Anatomical Therapeutic Chemical Classification System (ATC) 
codes as identifiers for the compounds [10]. Because of the multiple occurrences of some 
compounds in the ATC hierarchy, in later publications we used a new version, where the 
identifiers are standardized English International Nonproprietary Names (INNs) of the 
compounds. The properties of these two datasets and the results based on them are 
qualitatively the same.  
It seems to be a rational choice to use the chemical structure of the compounds as an 
identifier, but the possible salt forms and different tautomers make the mapping labour 
intensive, therefore in the case of approved drugs an identifier like INN is a more 
convenient choice. 
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Table 5 - Information sources used in the different phases of the work 
 Target Freq Preval 3D MACCS Molconn. TFIDF Used ID 
Method 
study (CMC) 
X X X X X X X ATC 
Amantadine 
study (FMC) 
X X  X X X X INN 
Parkinson's 
study (CTMC) 
 X  X X X X INN 
Multi-target X X  X X X X INN 
 
The target information source is special in a sense that it can biases the prioritization 
towards known targets. If we would like to be conservative, we can drop this information 
source to find out if our method can identify a target which is already known from the 
other sources (see Table 5). In the studies, where we compared two statistical methods, 
this bias is irrelevant because the extra knowledge can help both methods equally. An old 
version of side effect prevalence based data source (Preval) contained information only 
for approximately 100 drugs; we therefore decided to drop it from the second version of 
the dataset. 
The pairwise overlap of the data sources is presented in Table 6. For every pair of data 
sources the number of drugs present on both data source is given. In the diagonal the size 
of the data sources are presented. 
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Table 6 - Overlap of the data sources: The table contains the number of drugs 
occurring in two data sources simultaniously. The diagonal elements are the sizes of the 
data sources. 
 MACCS MOLCONN 3D FREQ TARGET TFIDF 
MACCS 1851      
MOLCONN 1823 1823     
3D 1754 1753 1755    
FREQ 532 519 511 543   
TARGET 1087 1074 1055 404 1162  
TFIDF 868 853 819 513 766 925 
 
MACCS: Molecular Access Keys (Schrodinger Suit 2012 Canvas) 
 
Figure 18 - Histogram of Tanimoto similarities based on MACCS keys (Number of drugs: 
1851, Mean similarity: 0.2786, Median similarity: 0.2708) 
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It is a MACCS key based binary fingerprint, where all binary features directly correspond 
to a question about the existence of a structural pattern defined by a Smiles Arbitrary 
Target Specification (SMARTS) query and no hashing or folding is applied. In this work 
we used the standard MDL definition with 166 queries. The histogram of the pairwise 
Tanimoto similarities is presented on Figure 18. 
 
MOLCONN-Z: Molecular Connectivity, Shape and Electrotopological fingerprint 
(Schrodinger Suit 2012 Canvas) 
 
We calculated the Molconn-Z electrotopological state (Estate) with all four options (Key, 
Count, Sum, Average) available in Schrodinger Canvas software, and concatenated the 
result to get a feature vector with maximal length of 352 for all compounds. The 
histogram of the pairwise cosine similarities is presented on Figure 19. 
 
3D pharmacophore based fingerprint (Schrodinger Suit 2012 Canvas) 
Figure 19 – Histogram of cosine similarities based on the MOLCONN-Z descriptor. 
(Number of drugs: 1823, Mean similarity: 0.4720, Median similarity: 0.5000) 
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The fingerprint is generated from triplets of pharmacophoric features and their distances. 
The conformers used for the analysis were generated during the fingerprint calculation 
process with default parameterization. The histogram of the pairwise Tanimoto 
similarities is presented on Figure 20. 
  
  
FREQ: Side Effect Frequencies 
This fingerprint was built based on the data we extracted from the SIDER database [51]. 
Every real valued feature corresponds to a side effect, and the value between 0 and 1 
measures the prevalence of this side effect in the treated population. The histogram of the 
pairwise cosine similarities is presented on Figure 21. 
Figure 20 – Histogram of Tanimoto similarities based on three dimensional 
pharmacophore fingerprint (Number of drugs: 1755, Mean similarity: 0.0380, Median 
similarity: 0.0600) 
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TARGET Known Drug-target interactions 
A binary descriptor based on validated targets of the drug, extracted from the DrugBank 
database [83]. Every feature corresponds to a biological target. Because the number of 
validated targets for a given drug is usually very small, even if the compound in practice 
can be quite promiscuous, these vectors are very sparse. 
Table 7 - Statistical properties of the pairwise Tanimoto similarities based on the 
Target data source 
Number of drugs: 
1162 
Tanimoto similarity 
Zeros removed Zeros not removed 
Mean similarity 0.3146 0.0082 
Median similarity 0.2000 0.0000 
 
Figure 21 - Histogram of cosine similarities based on side effect frequencies (Number 
of drugs: 543, Mean similarity: 0.1195, Median similarity: 0.0794) 
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Because of the sparseness of this relation, histogram is dominated by a peak at 0.0 
similarity level. Mean and median similarity calculated based only on the nonzero values 
(see Table 7). 
TFIDF Side effect related terms 
This one is a continuous valued descriptor, where each position corresponds to a relevant 
term and its value is the tf-idf score of the term in the package leaflet corpus. We used 
documents from the DailyMed database, which contains package leaflets submitted to the 
FDA [84]. These labels are stored in a standardized semi-structured XML format. They 
contain information about the active substances, manufacturer, indications, dosage, 
contraindications, possible drug interactions and side effects among others. 
To compute tf-idf score, first we need to compute the term frequency: 
where nij is the number of times term i appears in the document j, and dj is the length of 
document j in words. Here document j corresponds to the package leaflet of drug j. As a 
next step we need to compute the inverse document frequency, which measures how 
informative, in other words how specific, a term is in general: 
where ni is the number of the documents containing the term i, and N is the number of all 
documents. It is clear that if all documents contain a word, that word has very little 
information about the drugs. The tf-idf score is the product of tfij and idfi. 
We used the MedDRA (Medical Dictionary for Regulatory Activities) to create a 
dictionary of side effects in the form they are used in package inserts [85]. MedDRA is a 
standardized, international, officially adopted terminology to facilitate the sharing of 
regulatory information. It has a tree structure with five specified levels: System Organ 
Class (SOC), High Level Group Term (HLGT), High Level Term (HLT), Preferred Term 
(PT), and Lowest Level Term (LLT). Only PTs and LLTs were used to create this 
information source. Every position in a descriptor corresponds to a PT, and every LLT 
occurrence in the corpus was counted to the corresponding PT. For example the LLT 
Joint inflammation corresponds to the PT Arthritis. 
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We filtered these terms further using the UMLS (Unified Medical Language System) 
ontology [86], using only terms that are assigned for one of the following four UMLS 
semantic types: 
 Anatomical Abnormality 
 Finding 
 Natural Phenomenon or Process 
 Sign or Symptoms 
Because MedDRA is also part of the UMLS system, the filtering is directly applicable. 
  
Finally, a descriptor vector is formed for each drug from all tf-idfij scores corresponding 
to that drug id j. The histogram and the statistical properties of the pairwise cosine 
similarities are presented on Figure 22. 
 
Figure 22 - Histogram of cosine similarities based on side effect tf-idf scores in 
package leaflets. (Number of drugs: 925, Mean similarity: 0.1364, Median similarity: 
0.1057) 
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5.2 Redundancy and complementarity of the information 
sources 
To assess the common information content of these data sources, that is to evaluate their 
complementarity, we computed the Spearman correlations of all pairwise similarities 
(Table 8). Because the distribution of the similarities is very different kernel to kernel, 
the correlation of the ordering of these similarities is more suitable than a standard 
Pearson correlation. As it is discussed earlier, this ordering is equivalent to a quantile 
normalization approach, which maps the different empirical distributions to a uniform 
distribution. 
Table 8 - Spearman correlations between pairwise similarities based on different data 
sources using the ATC based kernels (*: p < 10-5; **: p < 10-10; ***: p < 10-20) 
α = 0.001  Target Sider Prev 3D MACCS TF-IDF Molconn 
Target - 0.4763 0.4927 0.4911 0.4941 0.4837 0.4743 
Freq *** - 0.1996 0.067 0.0637 0.1465 0.0006 
Prev *** *** - 0.1377 0.0762 0.2543 -0.0412 
3D *** *** * - 0.3798 0.0934 0.2764 
MACCS *** *** ** *** - 0.1343 0.4433 
TF-IDF *** *** *** *** *** - 0.0743 
Molconn *** not sig. not sig. *** *** *** - 
 
5.3 Evaluation framework for the fusion methods 
I participated in the development of the novel Kernel Fusion Repositioning (KFR), which 
method uses the one-class SVM framework and serves as a reference model class in the 
comparison of other data fusion methods. As the one-class SVM seems to be quite 
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insensitive to the parametrization in a prioritization setting, we just used a fixed parameter 
ν=0.4 for all of our experiments. In the late fusion setup we computed prioritization based 
on different data sources separately, and fused the ranking with the Borda protocol. We 
used the Lp-MKL formulation for the intermediate fusion, and we used an in house 
implementation of the SMO-MKL solver by Sun et al. extended with the one-class 
option [75]. 
 AUC[ROC], AUC[CROC(exp)], BEDROC and fixed threshold sensitivity and 
specificity measures were used to evaluate predictive performance. The early discovery 
focus was α=20.0. Two thresholds were introduced for both the sensitivity and the 
specificity: top25 and top100. We predicted the membership of Level 4 ATC classes and 
evaluated the performance with bootstrap cross-validation: 30% of the class members 
were randomly selected as a test set, and 70% were kept for training, using 100 repetitions. 
5.4 Drug-Indication reference set 
To evaluate the different data fusion methods we need a drug classification system which 
is widely accepted and defines the “gold standard” indications. ATC, a widely accepted 
classification system was utilized to compare the predictive performance of the different 
ranking methods. ATC is a five-level taxonomy maintained by the Collaboration Center 
for Drug Statistics Methodology of the World Health Organization. The first level, called 
the anatomical main group, is the most general group, based on the organ or system on 
which the drug acts, like dermatologicals or nervous system. The second level, called the 
therapeutic main group, indicates therapeutic categories like antihypertensives, 
immunosuppressants or analgesics. The third level can indicate therapeutic or 
pharmacological subgroups, like antidepressants, or opioids. The fourth level can indicate 
chemical, therapeutic or pharmacological subgroups, like sulphonamides, or selective 
serotonin reuptake inhibitors. It is important to note that the same compound can appear 
multiple times in the taxonomy if it has more than one indication. For example the 
macrolide tacrolimus has two different ATC identifiers: D11AH01 and L04AD02. The 
former corresponds to D (dermatologicals), 11 (other dermatological preparations), AH 
(non-corticosteroid agents for atopic dermatitis), while the latter is L (immunomodulators 
and antineoplastics), 04 (immunosupressants), AD (calcineurin inhibitors). 
DOI:10.14753/SE.2018.2060
71 
In the experiments we used the 95 Level 4 ATC classes from our dataset, which contained 
at least 6 drugs, without eliminating duplicated ATC identifiers. We omitted 6 categories 
because of their inhomogeneity: Other ophthalmologicals (S01XA), Detoxifying agents 
for antineoplastic treatment (V03AF), Antidotes (V03AB), Other nasal preparations 
(R01AX), Other plain vitamin preparations (A11HA), Other antineoplastic agents 
(L01XX), Other dermatologicals (D11AX), Electrolyte solutions (B05XA), and Other 
cardiac preparations (C01EB). 
5.5 Application for Parkinson's disease therapy 
Parkinson’s disease (PD) is one of the most well-studied neurodegenerative diseases 
characterized by the progressive loss of dopamine producing neurons in substantia nigra. 
As the research group at the Department of Organic Chemistry has interest in Parkinson's 
disease therapies, we applied the data fusion based methodology to prioritize 
repositioning candidates for Parkinson's disease (PD). [14]. Nevertheless, the developed 
methodology can be applied to a wide range of repositioning projects in general. 
According to our current knowledge all neurodegenerative diseases share, with different 
levels of importance, the following underlying mechanisms: oxidative stress, 
neuroinflammation, mitochondrial dysfunction, protein misfolding and aggregation, 
glutamate excitotoxicity, proteosomal dysfunction, disrupted intracellular transport and 
neurofilamental network, microglial activation and abnormal apoptotic behaviour [14, 
16].  
To apply the methodology on practical pharmacology problems, there are some common 
steps to be done [14]. These steps are the following: 
1. Definition of the broader prioritization goal 
The prioritization can be a single run or it can be a sequential process. The goal can be to 
find drugs for an indication, or to find an indication to a drug. In our specific application, 
the goal was to find FDA approved drugs with good repositioning potential as a PD 
therapy. 
2. Construction of the candidate list 
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We used the entire set of approved drugs as a candidate set. We could use any set, like a 
proprietary chemical library, or a subset of approved drugs. For example, as we search 
candidates for a central nervous system (CNS) related indication, we can pre-filter the 
candidates based on their blood-brain barrier penetration ability. Other options are 
filtering based on intellectual property considerations, toxicity related substructures or 
unwanted biological effects.  
3. Construction of special kernels 
As discussed earlier, the similarity of compounds can be assessed outside of the classic 
chemical representation space. One approach is the side effect based similarity, first 
applied by Campilos et al. and further discussed in one of our publications [10, 52]. Other 
rich sources of information can be constructed from chemically perturbed gene 
expression profiles, like from the CMAP or LINCS datasets [42, 87]. A use case for the 
application of CMAP profiles is discussed in detail in our work [12]. Another promising 
option is the incorporation of disease specific information sources, and expert knowledge 
through kernels. An interesting new possibility is the data source construction from High 
Content Imaging (HCI) screens [88]. 
4. Design and construction of the query 
An important property of the query is heterogeneity, as it is also discussed in the case of 
group fusion [26]. To a given limit, heterogeneity is desirable as it increases the 
probability of non-trivial hits. Too high heterogeneity on the other hand can lead to 
anomalous behaviour. We constructed four different queries representing four 
subcategories or mechanisms of action such as neuroprotective agents, dopaminergic 
agents, muscarinic agents, and NMDA antagonists (see Table 9). Designing a query for 
prioritization is equivalent to setting the focus of the in silico study. Intuitively, we need 
to describe the indication we are interested in with a set of compounds. According to our 
studies, an optimal query size is around 3-10 compounds, but the query size can deviate 
significantly from this value in special cases. 
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Table 9 – The four Parkinson’s disease related queries with their descriptions. 
 
5. Running the method and evaluating the performance 
There are diagnostic steps which can be done to rule out meaningless results. Checking 
the query heterogeneity – e.g. ISS/UAS value - before the run is the first diagnostic step. 
Checking the positions of the query compounds in the output list is also informative. If 
some candidate compounds got higher rank than some query compounds it can signal a 
strong hit, but if too many candidates had been ranked before the query it is a strong signal 
of extreme heterogeneity. 
6. Extracting knowledge from the ordering 
Query Description 
amantadine 
pramipexole 
rasagiline 
Neuroprotective agents: Agents with disease modifying 
effect and the ability of slowing or reversing disease 
progression. 
bromocriptine 
cabergoline 
pramipexole 
rotigotine 
Dopaminergic agents: Direct agonists of various 
dopamine receptors replacing the effect of the missing 
endogenous ligand. 
amantadine 
budipine 
ifenprodil 
memantine 
NMDA antagonists: Antagonists of the N-methyl-D-
aspartate sensitive ionotropic glutamate receptor, believed 
to protect against glutamatergic excitotoxicity [89]. 
benzatropine 
biperiden 
trihexyphenidyl 
Muscarinic antagonists: Agents used for reducing the 
relative cholinergic hyperactivity in the central nervous 
system caused by dopamine deficiency, restoring the 
striatal dopaminergic-cholinergic balance.  
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There are several ways to extract information from the resulted ordering, in addition to 
the investigation of the top hits. One option is to apply filters to lower the number of 
compounds we need to investigate. These filters can be chemical structure based or text 
mining based filters. We applied a PubMed based filter, where we filtered out compounds 
without co-occurrences with the terms “PD”, “Parkinson” or “Parkinson’s disease” in 
PubMed abstracts. Other options are filtering based on physicochemical properties, or 
based on functional group occurrences [90]. 
In addition to the filtering we can use enrichment analysis to test, if there is a property 
enriched in the top of the list. The application of the compound set enrichment analysis 
(CSEA)  is discussed in our publication [12]. Compound set here means compounds 
having common properties interesting for our purpose, like common mode of action, 
target, indication or side effect [12]. The idea originates from gene set enrichment analysis 
(GSEA) [91]. 
We used the SaddleSum algorithm for enrichment analysis [92]. The intuition behind the 
algorithm is rather simple. We are interested in the enrichment of certain annotations on 
the top of our prioritization list. We have a vocabulary V of compound sets; the members 
of each set shares the same annotation. In our examples we will use the ATC Level 4 
classes as annotations. We can collect a weight for every annotation by adding up the 
inverse rank or the score of all compounds sharing the given annotation. 
To answer the question 'Is the given annotation significantly enriched on the top of the 
list?' we have to ask how likely it is that if we randomly pick entities, the sum of weights 
exceeds S. This probability will be our p-value. If this probability is low, it is highly likely 
that the enrichment is not caused by chance. 
5.6 Evaluation of Macau 
I also participated in the development of the Bayesian matrix factorization method Macau 
for the drug-indication prioritization task. An important aim of the present work is to 
make the method applicable for settings without negative samples. The probability that a 
missing association does not hold is much higher than the probability that it exists but it 
has not been verified yet. In the research a well-established strategy was selected to 
randomly choose a subset of the missing associations identified as the negative set.  
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Using the 4th level of the ATC hierarchy, we created a 718 x 99 matrix where the rows 
represent compounds, and the columns represent ATC Level 4 classes. The created matrix 
is sparsely filled with 872 ones with average of 1.21 classes per compound, which 
corresponds to a fill rate of 1.2%. We used the same ATC class level as in the one-class 
SVM experiments to make the interpretation of the results easier. There are, however, 
factors making the strict comparison difficult. First of all, the one-class SVM experiments 
were carried out using ATC codes as identifiers, while the new version of the kernels uses 
INNs. Secondly, we use Macau as a least-square classifier in the PU learning setting 
discussed earlier, while the one-class SVM does not use any information about the non-
labelled compounds. Finally, Macau is capable of predicting multiple targets 
simultaneously.  
We left out the compounds for which the side information is unavailable in every 
experiment, therefore the real factorized matrix is somewhat smaller than 718 x 99 (See 
Table 10). 
Table 10 - The sizes of the matrices in the different Macau runs. 
Data source 
Drug–ATC class matrix Drug–Feature Matrix 
Number of drug Number of ones Num. of 
features 
Nonzero 
features 
MACCS 623 774 152 24166 
MOLCONN 617 768 348 22332 
3D 597 748 49710 387128 
TFIDF 485 620 2339 59459 
TARGET 534 658 1024 2080 
 
As we mentioned above, to predict the missing elements in the matrix we need to include 
zeros with a prior probability. We chose to randomly add 4 times as many zeros as known 
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membership relations and repeated this imputation 20 times. To validate that the multi-
task effect between ATC level 4 classes can improve our results we used a column-wise 
ridge regression (a form of regularized OLS regression) as a benchmark. 
5.7 Analysis of the methotrexate pharmacokinetics 
The second major topic of my thesis is pertaining to personalized medicine. Personalized 
medicine can help in the clinic by suggesting tailored therapies, and also in the 
pharmaceutical research, as it can facilitate more effective drug development. I 
participated in a research about analysing interpersonal variability of methotrexate 
pharmacokinetics at high dose levels in children with osteosarcoma. The aim of our study 
was to investigate possible genetic factors and their role in the inter-individual differences 
of the pharmacokinetics and toxicity of methotrexate. 
Osteosarcoma is a primary malignant bone tumour with the highest prevalence in the 
group of children and young adults. One of the established therapies is high dose 
methotrexate chemotherapy. The reduced elimination of this drug can lead to toxicities, 
especially hepato- and myelotoxicity. 
In the following I will describe a dataset collected at the 2nd Department of Paediatrics 
of Semmelweis University, and which I will use to demonstrate the application of the 
Bayesian multilevel relevance analysis in phamacokinetics studies. As a member of the 
research group I analysed the effect of 29 preselected single nucleotide polymorphisms 
(SNP) from the genes ABCB1, ABCC1, ABCC2, ABCC3, ABCC10, ABCG2, GGH, 
SLC19A1, NR1I2 (see the details in Table 11). In gene selection we significantly relied 
on the literature and on relevant scientific findings as well. When estimating functionality 
we relied on the classification of the polymorphism and its localization. The SNPs were 
ranked from the highest to the lowest functionality as non-synonymous, localization in 
the promoter region, localization in the 3' UTR region, synonymous and intronic 
localization. Only polymorphisms with minor allele frequency (MAF) greater than 10% 
were selected taking care to cover the most haplotype blocks possible.  
The isolation of the genetic material from blood was carried out by using Qiagen isolation 
kits (QIAmp DNA Blood Maxi Kit / QIAmp DNA Blood Midi Kit; Qiagen, Hilden, 
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Germany). For sequencing GenomeLab SNPstream genotyping platform (Beckman 
Coulter) was used.  
 
Table 11 - Selected SNPs for genotyping (table adapted from [60]). We will concentrate 
on the methodology in this work, therefore only properties relevant for the statistical 
analysis are presented. Detailed description of the biology can be found in our 
publication or in the doctoral thesis of Dr. Marta Hegyi [60, 93]. 
Gene SNP Alleles N11 (%) N12 (%) N22 (%) MAF (%) HWE 
ABCB1 
 
rs1045642 C/T 16 23 15 49 0.27 
rs1128503 C/T 16 29 14 48 0.28 
rs9282564 A/G 31 10 0 12 0.37 
ABCC1 rs4148358 G/A 32 11 2 17 0.42 
rs246219 G/A 38 9 1 11 0.59 
rs246221 A/G 25 17 5 29 0.42 
rs12922588 A/G 20 23 9 39 0.49 
rs215060 A/G 28 18 0 20 0.10 
rs4148330 G/A 17 22 4 35 0.40 
ABCC2 rs2273697 G/A 32 19 2 22 0.68 
rs3740066 G/A 23 21 8 36 0.39 
rs717620 G/A 28 13 1 18 0.72 
ABCC3 rs4793665 T/C 17 30 9 43 0.48 
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Gene SNP Alleles N11 (%) N12 (%) N22 (%) MAF (%) HWE 
rs2107441 A/G 16 23 6 39 0.61 
rs2412333 G/A 23 24 4 31 0.50 
rs733392 G/A 21 28 3 33 0.10 
rs12602161 A/G 37 14 0 14 0.10 
ABCC10 rs1214748 G/A 15 28 5 40 0.12 
rs831314 A/G 37 13 2 16 0.53 
rs1214752 G/A 19 18 8 38 0.31 
ABCG2 rs2231142 C/A 39 13 0 13 0.30 
GGH rs3758149 C/T 20 28 7 38 0.56 
SLC19A1 rs1051266 A/G 15 27 14 49 0.79 
NR1I2 
(SXR) 
rs7643038 A/G 16 20 9 42 0.55 
rs3814055 G/A 18 23 11 43 0.47 
rs1054190 G/A 36 12 0 13 0.32 
rs3732361 G/A 13 24 9 46 0.72 
rs3814058 A/G 25 16 3 25 0.84 
rs6785049 A/G 11 29 9 48 0.19 
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5.7.1 Patient data 
59 patients participated in the study, all of whom were diagnosed with osteosarcoma 
between 1988 and 2006 at the 2nd Department of Paediatrics of Semmelweis University. 
The participants are all Hungarian. Informed consent from patients or the parents was 
received, and the whole study was carried out according to the principles expressed in the 
Declaration of Helsinki, approved by the Hungarian Scientific and Research Ethics 
Committee of the Medical Research Council (case no.: 8-374/2009-1018EKU 914/PI/08.).  
The clinical data contain 551 blocks of methotrexate treatments, with the dosage of 
12g/m² body surface area, applied 4 to 12 times in every case. The patient database 
available for this study contains the following collected information: age at diagnosis; 
gender; risk-group; serum MTX level at 6h, 24h, 36h and 48h after treatment; lowest 
serum total protein; white blood cell count; neutrophil granulocyte count;  highest value 
of alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT);  bilirubin 
and creatinine during 2 week after treatment. 
The following derived measures of the pharmacokinetics were used: area under the 
concentration–time curve in the first 48 hour (AUC0-48), the peak methotrexate 
concentration, and the half-lives of methotrexate: T1 and T2 assuming two-compartment 
kinetics. T1 and T2 were derived using the serum level measurements before and after 
24h respectively. 
The main tool to analyse this database was univariate frequentist statistic (Pearson’s chi-
squared test), carried out and interpreted as a part of a parallel work [93]. We used the 
results of the Bayesian multilevel relevance analysis to complement and confirm the 
frequentist results in that work, specifically with respect to interactions. For the above 
mentioned reasons, here we will discuss details of the frequentist methodology only when 
it is essential for clear understanding. 
5.7.2 Bayesian multilevel relevance analysis 
We used Cooper-Herskovits (CH) non-informative structure prior for the analysis [94]. 
The maximal number of parents per node is a parameter of the method, which we set to 
4 and to 2 in two separate runs. This setting limits the space of all possible Bayesian 
network models in case of limited data availability. We used 200 million Markov-chain 
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Monte Carlo (MCMC) steps; one million out of which were discarded from the beginning 
as burn-in to ensure that our samples are drawn from the correct a posteriori distribution. 
We only accepted associations, which appeared in the case of both parent count setting. 
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6 Results 
6.1 Fusion of heterogeneous information sources for the 
prediction of the biological effect of small-molecular 
drugs 
The aim of the research we conducted into computational drug repositioning was to 
compare the predictive performance of the newly developed Kernel Fusion Repositioning 
(KFR) method as an intermediate fusion method and a standard late fusion method, the 
Borda protocol based fusion via using one-class support vector machines as the model 
class. The Level 4 ATC classes were used as prediction tasks. 
We computed AUC[ROC], AUC[CROC(exp)], BEDROC, TOP25 and TOP100 
Sensitivity and Specificity values for all prediction tasks, here ATC classes, and 
illustrated the result on boxplots (See Figure 23). Because of the high specificity values, 
they are also shown on Figure 24, with an appropriate range. 
Figure 23 - Comparison of the performance of the intermediate and the late fusion 
method. 
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We also calculated the number of ATC classes which are significantly better predicted by 
the two fusion methods according to all measures (t-test; p < 0.001). We have found that 
in all cases, primarily underpinned by the early discovery measures, the intermediate data 
fusion has better predictive performance. 
 
 
To illustrate the result of the prioritization, a heatmap with hierarchical co-clustering is 
generated (see Figure 25). Every row in the heatmap corresponds to a drug and every 
column corresponds to a level 4 ATC class. The map is coloured according to the 
predicted membership relation between the drug and the class. Red signifies strongly 
predicted memberships, while blue signifies weak or no relations at all. 
The hierarchical clustering organized the drugs with similar membership profiles, and the 
classes with similar members together, forming rectangular block structures in the map.  
 
Figure 24 - Comparison of specificities of the intermediate and the late fusion method. 
Figure 25 - Illustration of the drug–ATC class heatmap. Red colour signifies strong 
membership relations, blue signifies no membership relations. 
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An 8 x 16 (compound by ATC class) section of the heatmap in Figure 25 corresponds to 
some monoamine reuptake inhibitors shown on the Figure 26. All the drugs are either 
selective serotonin reuptake inhibitor (SSRI) (fluvoxamine, sertraline, paroxetine, 
fluoxetine, citalopram, escitalopram) or tricyclic antidepressants (protriptyline, 
nortriptyline). The red column shows the SSRI ATC class N06AB. There are 
antihistamine ATC classes (R06AD, R06AX, D04AA) in the neighbourhood, which can 
be a chemical structure related similarity, see e.g. fluoxetine and diphenhydramine. There 
are other classes like anti-obesity drugs (A08AA), erectile dysfunction related drugs 
(G04BE) or antiepileptics (N03AX) where the similarity can be anticipated based on 
biological knowledge. It is important to note that citalopram and escitalopram have 
slightly different profiles even with non-stereospecific chemical descriptors. This 
discrimination power comes from the other data sources.  
 
 
An additional direct output we can extract from the kernel fusion based technique is the 
weighting of the information sources (see Figure 27). The plot shows the average kernel 
weights of the 100 cross-validation runs. 
Figure 26 – Heatmap of monoamine reuptake inhibitor drugs and relevant ATC classes. 
Some of the relevant classes are: non-selective monoamine reuptake inhibitors 
(N06AA), SSRIs (N06AB), other antidepressants (N06AX), sympathomimetic (N06BA, 
R01AA, S01EA), centrally acting antiobesity products (A08AA), erectile dysfunction 
related drugs (G04BE), antihistamines (R06AX, R06AD, D04AA) and antiepileptics 
(N03AX). 
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Since the Borda method does not have explicit weights, we calculated the Spearman 
correlation of the ordering based on the given single data source and the output orderings 
of the two fusion methods to compare their behaviour (see Figure 28). This measure is 
univariate, while the kernel weighting is multivariate in nature. This means that if two 
information sources are redundant, the kernel weights will drop, while the correlation 
between the output and the single source models will not. 
 A notable feature of these results, also a key result of my work, is that the relative 
contributions of the different data sources are quite stable across the different drug 
Figure 27 - Parallel coordinates diagram of the kernel weights: the relative importance 
of the different data sources determined by the KFR algorithm. 
Figure 28 – Parallel coordinates diagrams of the Spearman correlations between the 
single source and the fusion models. The contributions are quite stable across the 
different drug categories in case of the Borda method (left), while the kernel fusion based 
method (right) shows adaptive, query-specific properties. 
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categories in case of the Borda method, while the kernel fusion based method shows 
adaptive, query-specific properties. 
We observed cases, independently of the fusion method, where the predictive 
performance is less than AUC = 0.5, which means it is worse than the performance of a 
random model. These anomalous cases have to be removed to ensure applicability. The 
following solution forms a key result of my work: we suggested a criterion on query 
compactness to define an acceptable training set for prioritization [10]. The proposed 
solution relies on the use of the intraset similarity (ISS) to measure the diversity of a 
training set, where ISS is the average of all pairwise similarities of the elements in the 
training set T: 
We normalized it with the average of all similarities in the full set of drugs: the universe 
of our experiment, called universal average similarity (UAS): 
The measure ISS/UAS shows a good correlation with AUC values as it is shown on Figure 
29.  It can be seen that all classes which have higher than one ISS/UAS value, have at 
least 0.5 AUC. 
 
Figure 29 - The correlation of the ISS/UAS measure and the predictive performance. 
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In Table 12 and Table 13 the 10 most compact and the 10 least compact ATC classes are 
presented with their average pairwise similarity (ISS) values. It can be seen that the most 
compact ones are defined based on target or chemical class, while the diverse ones are 
based on broad functional categories. 
Table 12 - The 10 most compact ATC Level 4 classes with the computed kernel-wise 
average ISS and ISS/UAS values. 
ATC Level 4 Name ISS ISS/UAS 
C07AB Selective beta blocking agents 0.40852 2.90816 
N02CC Selective 5HT1 agonists 0.40679 2.89581 
N06AB Selective serotonin reuptake inhibitors 0.40474 2.88124 
N05AB Phenothiazines with piperazine structure 0.38035 2.70757 
C09AA Angiotensin-converting enzyme inhibitors 0.35983 2.5615 
H02AB Glucocorticoids 0.35725 2.54319 
R06AA Aminoalkyl ether antihistamines 0.35109 2.49929 
L01DB Anthracyclines and related substances 0.34375 2.44708 
D07AB Corticosteroids, moderately active (group II) 0.33612 2.39275 
N04BC Dopamine agonists 0.33329 2.37259 
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Table 13 - The 10 least compact ATC Level 4 classes with the computed kernel-wise 
average ISS and ISS/UAS values. 
ATC Level 4 Name ISS ISS/UAS 
A06AD Osmotically acting laxatives 0.03782 0.26924 
V08AC Water soluble hepatotropic X-ray contrat media 0.04659 0.33164 
G01AA Gynecological antibiotics 0.04661 0.33178 
V08CA Paramagnetic contrast media 0.08047 0.57282 
D06AX Other antibiotics for topical use 0.08361 0.59510 
S02AA Otological antiinfectives 0.09246 0.65817 
D01AE Other antifungals for topical use 0.09879 0.70329 
B05XA Electrolyte solutions 0.10896 0.77562 
D06BB Antivirals for topical use 0.1135 0.80801 
A07AA Antibiotics, Intestinal 0.12187 0.48414 
 
The geometry of this anomalous behaviour is illustrated on Figure 30. If the query is not 
compact, like the set of red dots on the figure, the model which separates them from the 
origin will rank a lot of unrelated compounds higher than the query itself (dots between 
the two groups on the figure). The compound ranked as 9th is more similar to the 
subgroup formed by the 7th and the 5th than the compounds ranked in the first place. 
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Both the MKL method and the single data source method applied in this comparison are 
sensitive to this situation, therefore it does not influence the comparison. 
This behaviour, while presented here as anomalous, can be useful to detect outliers in a 
query, or what is the main goal here, to detect some novel entities with the same property 
as the query. 
  
Figure 30 - Geometric illustration of the anomalous behaviour in the case of a 
heterogeneous query. The query compounds (red dots) are so heterogeneous that they 
are not ranked at the top of the list. 
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6.2 Application of the Kernel Fusion Repositioning method 
for finding Parkinson's disease related drugs 
We analysed the result given to four Parkinson’s disease (PD) related queries composed 
of neuroprotective agents, dopaminergic agents, muscarinic agents and NMDA 
antagonists by the KFR system (see Table 14) [14].  
Table 14 - The four Parkinson's disease related queries 
Query Drugs 
Neuroprotective agents amantadine, pramipexole, rasagiline 
Dopaminergic agents bromocriptine, cabergoline, rotigotine, 
pramipexole 
Muscarinic agents biperiden, benzatropine, trihexyphenidyl 
NMDA antagonists ifenprodil, budipine, amantadine, 
memantine 
 
The neuroprotective query is the most heterogeneous one, containing compounds with 
different structural scaffolds and mechanisms of action, which can have an effect on the 
disease progression (See Figure 31).  
Amantadine is an adamantane derivative originally introduced to the market as an 
antiviral agent inhibiting the M2 protein of influenza A viruses [95]. It is a relatively weak 
Figure 31 - Neuroprotective agents with their assumed neuroprotective mechanisms 
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NMDA receptor antagonist and only indirectly increases dopamine release [89, 96]. 
Pramipexole is a dopamine agonist partially selective for D3 receptor and an antioxidant 
[97, 98]. Both enantiomers of pramipexole can inhibit the mitochondrial production of 
reactive oxygen species (ROS) [98]. Rasagiline is an irreversible monoamine oxidase B 
(MAO-B) inhibitor, and a well-tolerated drug in PD therapy [99]. The effect against 
oxidative stress is only partly due to its MAO-B inhibitory effect [100, 101]: the reaction 
catalysed by MAO-B itself leads to H2O2 production, and in the next step to ROS 
production by Fenton's reaction. Another possible mechanism is a direct antioxidant 
effect due to the presence of the propargyl moiety [102]. 
The dopaminergic agonist query contains two ergoline (bromocriptine, cabergoline) and 
two non-ergoline (rotigotine, pramipexole) compounds (see Figure 32). Besides being a 
dopamine agonist, pramipexole is also have an antioxidant effect [97, 98]. 
 
 
The NMDA antagonist query is also structurally diverse containing two adamantane 
derivatives: amantadine, memantine (see Figure 33). In addition to its NMDA antagonist 
activity budipine shows anti-muscarinic effect as well [104]. Ifenprodil shows 400 fold 
selectivity for the NMDA receptor subunit NR2B relative to NR2A [105]. 
Figure 32 - Dopaminergic agonists and their main targeted subtypes [103]. 
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The members of the muscarinic antagonist group illustrated on Figure 34. Both biperiden 
and trihexyphenidyl show NMDA antagonist property as well [107]. 
 
In Table 15 the result of the four prioritization runs is shown after the PubMed based 
filtering. For every query those top10 compounds are shown which have non-zero co-
occurrence number defined with the following PubMed search query: („Parkinson” OR 
„Parkinson's Disease” OR „PD”) AND INN. As the original filtering was based on the 
state of the PubMed in 2013, the number of the found abstracts is also shown in case of a 
repeated search on the September 2016 version of the database. From a prospective point 
of view, which is the most reliable evaluation, it is interesting to note that the co-
occurrence number for some of the highly prioritized compounds increased significantly. 
For example it is increased by 176% for clonidine and by 200% for gabapentin, while the 
relative increase was less significant for others (eg.: trihexyphenidyl or pergolide) or there 
was no change at all (eg.: encainide). These three groups show good correspondence with 
the following groups: possible repositioning candidates, already known drugs and false 
positives. 
Figure 33 - NMDA antagonists with their specific features. Budipine shows anti-
muscarinic effect [104], while ifenprodil shows selectivity based on NMDA receptor 
subunits [105, 106]. 
Figure 34 - Muscarinic antagonists with their targets [103]. 
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Table 15 - Result of the prioritization with PD related queries. The prioritization list 
was filtered based on PubMed co-occurrence. 
Query Description 
Query elements 
with their resulted 
rank 
Result 
Ranking 
PubMed hits 
2013/2016 
Neuroprotective 
agents 
1 amantadine 
2 pramipexole 
3 rasagiline 
5 memantine 77 / 166 
6 pergolide 442 / 550 
7 tacrine 30 / 45 
9 ropinirole 335 / 485 
12 gabapentin 20 / 60 
21 fentanyl 33 / 91 
24 ziprasidone 24 / 42 
25 clonidine 43 / 119 
26 chloroquine  11 / 55 
29 clozapine. 289 / 446 
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Query Description 
Query elements 
with their resulted 
rank 
Result 
Ranking 
Query 
Description 
Dopaminergic agonists 1 bromocriptine 
2 cabergoline 
3 pramipexole 
4 rotigotine 
Ranking 
PubMed hits 
2013/2016 
6 pergolide 442 / 550 
7 lisuride 240 / 272 
8 apomorphine 1105 / 1787 
9 risperidone 83 / 155 
10 aripiprazole 27 / 67 
11 ziprasidone 24 / 42 
13 olanzapine 92 / 161 
14 quetiapine 125 / 198 
15 ergotamine 12 / 16 
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Query Description 
Query elements 
with their resulted 
rank 
Result 
Ranking 
PubMed hits 
2013/2016 
NMDA antagonists 1 ifenprodil 
2 budipine 
3 amantadine 
4 memantine 
8 dextromethorphan 19 / 46 
12 pergolide 442 / 550 
13 aprindine 21 / 21 
16 benzatropine 59 / 75 
19 mianserin 13 / 31 
20 imipramine 59 / 119 
21 biperiden 70 / 92 
23 encainide 25 / 25 
25 trihexyphenidyl 229 / 274 
29 donepezil 71 / 133 
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Query Description 
Query elements 
with their resulted 
rank 
Result 
Ranking 
Query 
Description 
Muscarinic antagonists 1 biperiden 
2 benzatropine 
3 trihexyphenidyl 
4 procyclidine 33 / 41 
7 atropine 119 / 253 
21 dextromethorphan 19 / 46 
24 rotigotine 110 / 236 
32 perphenazine 37 / 54 
35 ajmaline 118 / 119 
38 quinidine 110 / 144 
40 haloperidol 335 / 665 
41 encainide 25 / 25 
42 donepezil 71 / 133 
 
Beyond simply applying filters to lower the number of compounds we need to investigate, 
there are several other ways to extract information from the resulted ordering. One option 
is to use enrichment analysis to test if there is a property which is overrepresented in the 
top of the list. The application of enrichment analysis is discussed in our publication [12]. 
As an illustration, we show the application of CSEA, which can be seen as an extension 
of the prioritization method, which is also developed in our research group. 
Using the information sources discussed in this work, and in addition a Connectivity Map 
based source described in our publication, we prioritized all compounds based on the 
similarity to amantadine [12]. We then calculated the enrichment of all ATC Level 4 
classes in that list which is shown in Table 16. The original study is more detailed, 
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suggesting continuous information management through the drug discovery pipeline. 
However, since it is outside the scope of this thesis, here we refer to the original 
publication [12]. 
Table 16 – ATC Level 4 classes enriched in the list ordered by similarity to amantadine 
using all information sources + CMAP profiles. Detailed application scenario for 
CSEA is published in our paper [12]. 
Rank ATC4 Name E-value 
1. N04BC Anti-Parkinson / Dopamine agonists 0.66352 
2. G03CC Estrogens, combinations with other drugs 3.22836 
3. G02CB Prolactine inhibitors 3.64457 
4. C03CA Sulfonamides 4.10682 
5. C02CC Guanidine derivative antihypertensives 5.93538 
6. N05AB Phenothiazine antipsychotics with piperazine structure 7.72258 
7. A03FA Propulsives 7.95207 
8. N05AE Indole derivative antipsychotics 8.59378 
9. N07BB Drugs used in alcohol dependence 11.0787 
10. N04AA Anti-Parkinson / Tertiary amine anticholinergics 11.8485 
 
As it is known that amantadine does not bind to the dopamine receptors, the presence of 
the class N04BC, or the classes G02CB, A03FA, N05AA which are rich in dopaminergic 
agents suggests indirect action on the dopaminergic system, which is well-known [108]. 
Other anti-Parkinson medications, like the ones in N04AA, also have an indirect effect 
on dopaminergic signalling [109].  
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6.3 Predicting multiple activities simultaneously improves the 
accuracy 
Every level 4 ATC class contains a relatively low number of drugs, therefore learning a 
classifier which can generalize well is not easy. Some classes, however, show 
considerable similarity to one another. If two learning tasks are similar, we can use this 
similarity to learn them together, and this way we can increase the information available. 
To test this hypothesis we evaluated the predictive performance of Macau, described in 
Section 3.17, and compared it with a set of class by class trained regression models. As 
there is no negative set available, we used unscreened controls. For every positive sample 
in our dataset we randomly selected 4 membership relations from the unlabelled drug-
class pairs and used them as negative set. We repeated this procedure 20 times, and using 
all the 20 datasets we trained models and averaged the predictions. The AUC values were 
computed for every ATC class using these aggregated predictions, and then these AUC 
values were averaged over the classes. 
As Macau is a Bayesian method we do not need to set parameters to get the optimal 
performance. The only parameter we need to choose is the number of latent dimensions, 
but we know from our previous studies that choosing the latent dimension parameter 
slightly larger than necessary does not deteriorate the predictive performance [79, 80]. 
The correct strategy to choose the latent dimension parameter is to increase it as long as 
the performance increases, as larger value makes the algorithm slower without any gain. 
The ridge regression has a regularization parameter λ, which we chose using a grid search, 
trying the values 0.01, 0.1, 1.0, 10.0, 100.0, 1000.0 and evaluated the performance using 
30:70 class-level cross-validation. 
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Table 17 - Comparison of the average AUC of Macau and ridge regression. Macau is 
superior in all cases. 
Information 
source 
Macau Ridge regression 
Latent dims. CV-AUC Regularization CV-AUC 
MACCS 16 0.9135 10.0 0.8860 
3D 16 0.9213 10.0 0.8226 
MOLCONN-Z 12 0.9139 0.01 0.7316 
TFIDF 16 0.8701 0.1 0.8559 
TARGET 16 0.9146 0.1 0.8416 
 
The result of the comparison is shown in Table 17. In all of the cases Macau has a 
considerably higher predictive performance than ridge regression. Presumably, Macau 
does not need as high-quality features as a single target method. One role of the feature 
in that case is to link compounds together and make the transfer of information between 
them possible.  
Figure 35 - Histogram of drugs involved in multiple classes. Most of the drugs involved 
only in one ATC level 4 class. 
DOI:10.14753/SE.2018.2060
99 
As the drug–ATC class matrix is very sparse, matrix factorization without side 
information cannot work on this dataset simply because most of the drugs are present 
only in one class (see Figure 35). This linking role can explain the relatively good 
performance of the MOLCONN-Z descriptor in the case of Macau, while it is a relatively 
poor predictor alone. 
6.4 Comparison of BN-BMLA results to frequentist statistics 
in the task of associated variance detection for 
interpersonal methotrexate pharmacokinetics variability 
As the clinical data contains 551 methotrexate blocks for 59 patients with a variable 
number of blocks per patient, the aggregation of the block level variables was necessary. 
I recommended using the median value over blocks for every variable as a patient level 
value, a convention used both in the frequentist and the Bayesian analysis. All 
pharmacokinetics and toxicity measurements were recorded at block level, therefore the 
median was computed. 
To apply the BN-BMLA method the discretization of the continuous variables is 
necessary. I suggested the discretization based on median values to get a balanced dataset 
with an equal number of samples for different values. In case of multinomial variables 
we applied binning to binary variables to reach lower model complexity. The original 
hepatotoxicity and myelotoxicity variable was multinomial with four possible values. 
Based on the balanced dataset criterion the team binned the myelotoxicity as grade 1 vs. 
grade 2-4, and the hepatotoxicity as grade 1-2 vs. grade 3-4. 
Both the toxicity variables (myelotoxicity, hepatotoxicity) and the pharmacokinetics 
parameters (AUC0-48, peak methotrexate concentration, and methotrexate half-lives) 
show a strongly interconnected correlation structure with one another and with other 
clinical parameters. The BN-BMLA models show a connection between the 
pharmacokinetics (AUC0-48, peak concentration) and the toxicity with a posteriori edge 
probability greater than 0.5. This connection was found based on frequentist methods as 
well [93]. There is also a strong link between the time of diagnosis (1988-1995 vs. 1996-
2006) and the clinical parameters, which is due to the well-known fact of the different 
applied clinical protocol in these two periods [93]. 
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In case of the NR1I2 gene two haplotype blocks can be identified. One of them is made 
up of two SNPs, the other is composed of three (see Table 18). 
Table 18 - Haplotype blocks in the NR1I2 (SXR) gene. (D’: normalised linkage 
disequilibrium constant, LOD: log of the likelihood odds ratio, r2: correlation 
coefficient) [110] 
SNP1 SNP2 D' LOD r2 
Block 1 
rs7643038 rs3814055 1.0 [0.91 – 1.0] 19.95 0.957 
Block 2 
rs3732361 rs3814058 1.0 [0.9 – 1.0] 17.47 0.916 
rs3814058 rs6785049 1.0 [0.76 – 1.0] 6.66 0.437 
rs6785049 rs3732361 1.0 [0.9 – 1.0] 17.47 0.916 
 
The frequentist approach found all NR1I2 polymorphisms in the second block associated 
with heptato- and myelotoxicity, while the BN-BMLA identified a single one in the 
multiple target case. This SNP (rs3814058) is the same as the one where the frequentist 
p-value indicates the strongest interaction, which shows that the BN-BMLA methodology 
can distinguish between direct relations and transitive relations. It is important to note 
that every statement about a direct relevance can be interpreted only with the assumption 
that there is no other unmeasured variable which can change the chain of relevance 
relations. It is possible for example, that there is another polymorphism which has a real 
functional role, and even the identified rs3814058 SNP is only a marker, which is 
associated because it is in linkage disequilibrium with the functional polymorphism. 
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Table 19 - Effect size of identified SNPs. Effect size measured by the change of AUC 
and T1 half-life, and by odds ratio (OR) in case of hepato- and myelotoxicity. 
Frequentist Bayesian Gene SNP AUC T1 Hepato Myelo 
X  ABCC2 rs3740066 +2.8% +2.0% 0.7778 0.2698 
X  ABCG2 rs2231142 -16.3% -8.3% 0.7742 0.3482 
X  
NR1I2 
rs7643038 +16.2% +18.9% 0.7653 0.5714 
X  rs3814055 +7.3% +16.6% 0.7653 0.5714 
X  rs3732361 -5.7% -1.8% 0.5625 0.9333 
X  rs6785049 -1.5% +1.5% 1.4624 1.5111 
X X rs3814058 +2.2% +7.9% 0.3333 1.6714 
X X ABCB1 rs9282564 +16.0% -0.9% 1.0345 0.4952 
X X ABCC3 rs4793665 +10.5% +4.5% 1.0909 0.8182 
X X ABCC2 rs717620 +26.5% +16.2% 1.6800 0.2667 
 X ABCC1 rs246219 -6.2% -2.3% 1.5714 2.6154 
 X GGH rs3758149 +15.4% +21.8% 0.5000 3.2500 
 
While some SNPs are identified by both frameworks (two SNPs in case of AUC, and one 
in case of myelotoxicity), there are weaker candidates suggested by both the frequentist 
and the Bayesian methodology (see Table 19). Our results suggest that using the 
consensus of different methods for robust detection of association is an appropriate 
pragmatic approach to be followed. 
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7 Discussion 
7.1 Fusion of heterogeneous information sources for the 
prediction of biological activity 
The major goal of the research we conducted into drug repositioning was to compare the 
late fusion and the intermediate fusion paradigm via using the small molecule - ATC class 
membership prediction task as a gold standard. We found that the intermediate fusion 
shows better performance both in the case of unweighted AUC measure, and in the case 
of early discovery setting. In accordance with other observations in the literature we 
hypothesise that the difference is mainly due to the capability of the intermediate fusion 
to distinguish between within-source and between-source interactions [73], as it is 
beneficial to restrict the modelled correlation structure of the input space in case of high 
input dimensionality [74]. In the extreme case of dropping all interactions between 
features, we get the naive Bayes classifier [111], a well-known, simple and well-
performing model in the case of high input dimensionality and a relatively small number 
of samples. 
Our results showed that the model is capable of reconstructing meaningful membership 
relations, and deriving similarity between drugs and between classes. We illustrated this 
fact using the example of the SSRI and tricyclic antidepressant drugs on a co-clustered 
heatmap. 
We witnessed that there is an optimal level of query heterogeneity. An appropriate level 
of heterogeneity can help us discover new results, but if the query is extremely 
heterogeneous, an anomalous behaviour takes place. In that case most of the candidate 
set is prioritized higher than the query. One of my key contributions was a diagnostic 
criterion, which can be used to filter these anomalous cases. 
Our method is able to determine weights for the information sources simultaneously with 
the prioritization. The optimization of these data source weights with the primary goal of 
good predictive performance results in a very intuitive criterion. The optimal weights are 
those which make the query as compact as possible. For example, if a query is chemically 
compact, the chemical descriptors will get high weights. This adaptive weighting results 
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in a different level of incorporation of the data sources depending on the query. This 
property is an important advantage, which makes the method applicable in a wide range 
of pharmacological groups and different chemical spaces.   
From a machine learning point of view, the problem discussed here is very similar to the 
problem of gene prioritization [112]. In case of gene prioritization the goal is to predict 
gene-disease associations, and we use a set of genes to represent a disease. Support vector 
machines and Multiple Kernel Learning were applied successfully in gene prioritization 
as well [113, 114].  
7.2 Application of the Kernel Fusion Repositioning 
framework to find Parkinson's disease related drugs 
The developed prioritization method was applied to search for Parkinson's disease related 
drugs, and it was able to identify other drugs used in the treatment of Parkinson's disease 
or co-occurring with the disease in the literature. 
The prioritization for dopaminergic agonists clearly shows one of the limitations of our 
approach. We retrieved 5 antipsychotics in the top10 filtered list, which are well known 
antagonists at different dopaminergic receptors, particularly at D2. Predicting target 
binding is evidently an easier task than predicting the functional role. This behaviour is 
expected even in case of the chemical structure based prediction, but it is more profound 
in case of the target data source. This source contains only the targets known for a given 
drug while the nature of the interaction on the targets are not encoded. The side effect 
data source can ameliorate this fallacy to some extent as side effects are consequences of 
functional effects. This phenomenon shows the importance of system level information 
sources like the side effect based profiles or gene expression profiles. 
Our PubMed based filtering is clearly suboptimal as it removes totally new repositioning 
candidates while still leave false positives in the list. For example antipsychotics are not 
only used in the treatment of Parkinson's related psychosis, but they can also cause 
symptoms similar to Parkinson's disease. This filtering will therefore not eliminate the 
false positives generated by the fact that functional interaction prediction is difficult in 
our context. It is crucial to consider that a bad filtering can have a serious detrimental 
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effect on the predictions. However, if we use the PubMed co-occurrences in a prospective 
way, we can get much more credible signals.  
Finally, we demonstrated the use of enrichment analysis tools in the interpretation of the 
Kernel Fusion Repositioning results. With enrichment analysis we showed that KFR is 
capable of retrieving different but related mechanism of actions to a query compound. 
7.3 Prediction of multiple targets simultaneously 
Our goal was to compare multiple target prediction with the classical single target 
prediction and we found that the predictive power is consequently higher for the multi-
target method in case of each information source. Similar results were found in our 
previous pharmacogenomics studies predicting median inhibitory concentration (IC50) 
values of compounds simultaneously on multiple targets [79]. 
Macau has a limitation in the area of fusion of multiple side information, as it can handle 
only fully observed side information. Side information matrices available for a different 
set of compounds cannot be concatenated. One option would be to drop all compounds 
which are not represented in all information sources, but it would result in a great waste 
of the available data. Other methods relying on the kernel trick have complementary 
application profile to Macau. While the latter is optimized for millions of matrix rows, 
here compounds, other methods are more suitable for a lower number of matrix rows but 
in exchange for a large number of features and several different information sources [115, 
116]. On the other hand, we are working on making Macau capable of incorporating non-
complete side information expressed in a non-kernelized form. 
7.4 Advantages of Bayesian methods 
The application of two novel Bayesian methods was discussed in the present work. In the 
following the common advantages of these methods will be discussed focusing on their 
theoretical relatedness. 
We found direct probabilistic statements useful in both application areas. In the case of 
BN-BMLA the feedback of researchers in the field of genetics suggests that direct 
probabilistic statements are more natural than the frequentist viewpoint centred on the 
Type I (false positive) error. We have a similar experience with Macau: we got a specific 
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request to show a measure of credibility for our predictions to the pharmaceutical 
development team in an industrial scale drug-protein interaction prediction project. These 
questions are typically in the following form: “What is the probability that I will get a hit 
with IC50 < 10μM if I test compound1 in my assay?”. 
Furthermore, these methods offer some convenient advantages both in exploratory data 
analysis and in black-box modelling. In classical frequentist association studies we need 
to correct for multiple hypothesis testing as our main concern is the false positive type of 
error. The simplest solution is to use Bonferroni correction, which means we divide our 
significance level by the number of tests. This seriously reduces our statistical power 
because of the assumption of total independence between tests. We can apply more 
sophisticated correction mechanisms, but in case of multivariate Bayesian modelling we 
do not need to do so, as it is implicitly handled by the framework [117]. This implicit 
“correction” corresponds to the dependence structure of the variables and it is not more 
conservative than necessary. 
In case of black box modelling, as all model parameters are treated as variables, their 
distributions are determined in the same framework as the prediction. Cross-validation 
does not need to be used to set the parameters. The only step to be handled is prior 
selection: we either use expert knowledge or select our priors to be non-informative. 
Another significant advantage of Bayesian models is that they usually outperform their 
frequentist alternatives especially in the case of low sample sizes. It is observed that the 
Bayesian Probabilistic Matrix Factorization (BPMF) approach, one of the successors of 
Macau, outperforms the non-Bayesian matrix factorization especially in rows which are 
really sparse [118].  
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8 Conclusions 
The results of my research allows for making the following conclusions and statements: 
 While conducting my research I significantly contributed to and participated in 
the development process of a novel intermediate data fusion method, the Kernel 
Fusion Repositioning (KFR) framework. Our research evaluations showed that 
KFR has a superior performance compared to the late fusion baseline Borda 
protocol as justified by the AUC measure, and especially verified by all applied 
early discovery measures in terms of a drug repositioning benchmark problem. 
 In order to examine the behaviour of the methods I analysed the Spearman’s rank 
correlation of the single data source based prioritization results with the data 
fusion based prioritization results and we found that KFR shows adaptive, query-
driven properties. This property is an important advantage, which makes the 
method applicable in a wide range of pharmacological groups and different 
chemical spaces.   
 The experiments showed an anomalous behaviour in case of extremely high query 
heterogeneity and we witnessed that the query compounds are not ranked high in 
the resulted ordering. In this case the predictive power of the method can be really 
poor. We suggested a criterion measuring the average pairwise similarity of the 
query compounds to filter these cases, and showed that this criterion can identify 
the queries resulting in poor predictive performance. 
 The KFR framework was applied to identify potential repositioning candidates in 
Parkinson’s disease therapy and compounds showing high co-occurrence with 
those in the literature were retrieved. All results were validated further in a 
prospective evaluation. Also, steps of a novel computational route for drug 
repositioning candidate identification were outlined. 
 I participated in the development process of Macau, a novel Bayesian matrix 
factorization method capable of predicting multiple targets simultaneously. While 
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conducting the research I compared Macau to a single target method (Ridge 
regression) and found it superior in the case of all information sources. 
 My research justifies successful adaptation and application of BN-BMLA, a novel 
multivariate Bayesian method, in complementing and confirming the already 
existing frequentist results in a study conducted into the pharmacokinetics of high 
dose methotrexate therapy. The results suggest that the effective combination of 
the Bayesian and frequentist methods in the field of the robust detection of 
association is an appropriate strategy, whereas the BN-BMLA method is more 
beneficial in the case of investigating interactions or redundancies, such as linked 
polymorphism. 
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9 Summary 
As the research and development productivity decreases, the pharmaceutical industry is 
continuously searching for new approaches in drug discovery to keep their business 
operational. Two possible options discussed in my work are drug repositioning and 
personalized medicine. In the age of big data, shared databases and precompetition time 
collaboration; information technologies, statistics and machine learning play an important 
role in these fields. 
I significantly contributed to an interdisciplinary project in which we designed and 
implemented a data fusion method called Kernel Fusion Repositioning (KFR). KFR can 
predict the biological effects of small-molecular drugs using a diverse set of 
heterogeneous information sources. In my doctoral research I demonstrated that the 
kernel fusion framework shows better predictive performance than the early data fusion. 
The results show that there is an optimal level of heterogeneity of the query to discover 
new indications without getting anomalous behaviour. 
The data fusion method was applied in order to identify Parkinson's disease related drugs. 
We observed that the method is capable of retrieving other drugs used in the clinical 
practice or drugs co-occurring in the literature with Parkinson's disease. Also, steps of a 
novel computational route for drug repositioning candidate identification were outlined. 
I participated in the development of Macau, a novel Bayesian matrix factorization method 
capable of predicting multiple targets simultaneously. While conducting the research I 
compared Macau to a single target baseline and found it superior in the case of all 
information sources. 
In addition to drug repositioning I also participated in a research project conducted into 
the pharmacokinetics of methotrexate at high dose levels. I adapted and applied a novel 
Bayesian multivariate statistical technique to identify predictive genetic variants for the 
interpersonal variability of methotrexate pharmacokinetics. Polymorphisms significantly 
overlapping with those independently discovered by frequentist methods were 
successfully retrieved, and the advantages of the new method were verified in case of 
linked polymorphisms and multiple target variables. 
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10 Összefoglalás 
Ahogy a kutatás-fejlesztés hatékonysága csökken, a gyógyszeripari vállalatok a 
gyógyszerfejlesztés új irányaira kényszerülnek, hogy továbbra is releváns piaci szereplők 
maradjanak. A dolgozatomban tárgyalt két lehetséges út a gyógyszer újrapozícionálás és 
a személyre szabott gyógyászat. A megosztott adatbázisok és a korai fázisú 
gyógyszeripari együttműködések korszakában nagy szerep jut az információtechnológia 
és a gépi tanulás módszereinek. 
Jelentős szerepet töltöttem be egy adatfúziós módszer, a Kernel Fusion Repositioning 
(KFR) keretrendszer megtervezését és implementálását célzó interdiszciplináris 
kutatásban. A KFR rendszer alkalmas kismolekulás vegyületek biológiai hatásának 
előrejelzésére heterogén információforrások felhasználásával. A doktori munkám során 
megmutattam, hogy a kernel fúziós keretrendszer előrejelzési pontossága felülmúlja az 
úgynevezett korai adatfúziós megközelítés eredményeit. Az eredmények tükrében 
kijelenthető továbbá, hogy létezik a lekérdezési gyógyszerhalmaznak egy optimális 
heterogenitása, amely mellett feltárhatók új indikációk ugyanakkor elkerülhető a módszer 
rendellenes működése. 
Ezt követően Parkinson-kór kezelése szempontjából releváns gyógyszerjelöltek 
keresésére alkalmaztam a fenti adatfúziós eljárást, és megfigyeltem, hogy a módszer 
alkalmas klinikai gyakorlatban alkalmazott gyógyszerek és az indikációt tekintve új, a 
szakirodalomban a Parkinson-kórral együttesen előforduló vegyületek megtalálására. 
Továbbá vázoltam egy számítógépes módszereket használó újszerű munkafolyamat 
lépéseit, mely alkalmas újrapozícionálási jelöltek azonosítására. 
Részt vettem egy több célváltozó együttes becslésére képes mátrix faktorizációs módszer, 
a Macau kifejlesztésében. Jelen kutatás keretében összehasonlítottam a Macau-t egy 
egyváltozós módszerrel, és a pontosabbnak találtam a használt információforrástól 
függetlenül. 
A fentieken túl részt vettem egy kutatásban, amely a nagy dózisban adagolt metotrexát 
farmakokinetikáját vizsgálta. Adaptáltam és alkalmaztam egy új Bayes-i többváltozós 
statisztikai technikát a metotrexát farmakokinetika betegenkénti variabilitásának 
szempontjából prediktív genetikai variánsok azonosítására. Az általam azonosított 
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polimorfizmusok jelentős átfedést mutattak a frekventista módszerek használatával 
azonosítottakkal. Ezen felül megmutattam az új módszer előnyeit kapcsolt 
polimorfizmusok és több célváltozó együttes vizsgálata esetén. 
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